<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003960.pub3" GROUP_ID="IBD" ID="023701092615124840" MERGED_FROM="" MODIFIED="2008-06-12 19:14:51 +0200" MODIFIED_BY="John MacDonald" REVIEW_NO="47" REVMAN_SUB_VERSION="5.0.12" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-06-12 19:14:51 +0200" MODIFIED_BY="John MacDonald">
<TITLE>Tegaserod for the treatment of irritable bowel syndrome and chronic constipation</TITLE>
<CONTACT MODIFIED="2008-06-12 19:14:51 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="14347" ROLE="AUTHOR"><FIRST_NAME>Beti</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Evans</LAST_NAME><EMAIL_1>b.w.evans@herts.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Pharmacy</DEPARTMENT><ORGANISATION>University of Hertfordshire</ORGANISATION><ADDRESS_1>College Lane Campus</ADDRESS_1><CITY>Hatfield</CITY><ZIP>AL10 9AB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 170 728 1052</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-06-12 19:14:51 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="14347" ROLE="AUTHOR"><FIRST_NAME>Beti</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Evans</LAST_NAME><EMAIL_1>b.w.evans@herts.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Pharmacy</DEPARTMENT><ORGANISATION>University of Hertfordshire</ORGANISATION><ADDRESS_1>College Lane Campus</ADDRESS_1><CITY>Hatfield</CITY><ZIP>AL10 9AB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 170 728 1052</PHONE_1></ADDRESS></PERSON><PERSON ID="14345" ROLE="AUTHOR"><FIRST_NAME>Wendy</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Clark</LAST_NAME><ADDRESS><DEPARTMENT>Medicines Management</DEPARTMENT><ORGANISATION>Keele University</ORGANISATION><ADDRESS_1>Department of Medicines Management</ADDRESS_1><ADDRESS_2>Keele University</ADDRESS_2><CITY>Newcastle-under-Lyme</CITY><ZIP>ST5 5BG</ZIP><REGION>Staffordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1782 584203</PHONE_1><FAX_1>+44 1782 713586</FAX_1></ADDRESS></PERSON><PERSON ID="14357" ROLE="AUTHOR"><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><EMAIL_1>d.j.moore@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Aggressive Research Intelligence Facility</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><ADDRESS_1>Aggressive Research Intelligence Facility</ADDRESS_1><ADDRESS_2>Department of Public Health &amp; Epidemiology</ADDRESS_2><CITY>University of Birmingham</CITY><ZIP>B15 2TT</ZIP><REGION>West Midlands</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 414 7449</PHONE_1><FAX_1>+44 121 414 7878</FAX_1></ADDRESS></PERSON><PERSON ID="14370" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Whorwell</LAST_NAME><POSITION>Consultant Physician &amp; Senior Lecturer in Medicine</POSITION><EMAIL_1>Peter.Whorwell@smuht.nwest.nhs.uk </EMAIL_1><ADDRESS><DEPARTMENT>Medical Academic Department</DEPARTMENT><ORGANISATION>Wythenshawe Hospital</ORGANISATION><ADDRESS_1>First floor,  Education and Research Centre</ADDRESS_1><ADDRESS_2>Southmoor Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M23 9LT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 291 5813</PHONE_1><FAX_1>+44 161 291 5806</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-12 12:27:01 -0400" MODIFIED_BY="John K MacDonald">
<UP_TO_DATE>
<DATE DAY="31" MONTH="7" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="5" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="12" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="31" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-12 12:31:05 -0400" MODIFIED_BY="John K MacDonald">
<SUMMARY>
<TITLE>Tegaserod for the treatment of irritable bowel syndrome and chronic constipation</TITLE>
<SUMMARY_BODY>
<P>Irritable bowel syndrome (IBS) is a chronic, relapsing condition characterized by the presence of abdominal pain and disturbed bowel habit. Symptoms of chronic constipation frequently resemble those of constipation-predominant IBS. Tegaserod (4 or 12 mg/day for 12 weeks), a drug that stimulates smooth muscle in the gastrointestinal tract, produces some benefit over placebo when used to treat IBS where constipation is a major symptom. Patients taking tegaserod reported an overall improvement in their IBS symptoms, an increase in number of bowel movements per day and a reduction in number of days without bowel movements. It is not clear if tegaserod improves symptoms such as abdominal pain, bloating, stool consistency and straining. When used to treat chronic constipation, the frequency of bowel movements increased with tegaserod, but increases over those seen with placebo were small. Diarrhea occurred more often among individuals taking high dose tegaserod (12 mg/day). Further studies are needed to assess the effect of tegaserod on quality of life. More information is needed on its effectiveness in men, as most of the studies involved women.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>IBS is a complex disorder that encompasses a wide profile of symptoms. The symptoms of chronic constipation frequently resemble those of constipation-predominant IBS. Current drug treatments for irritable bowel syndrome (IBS) are of limited value. Many target specific symptoms only. Tegaserod, a 5HT<SUB>4</SUB> partial agonist, represents a novel mechanism of action in the treatment of IBS and chronic constipation. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to evaluate the efficacy and tolerability of tegaserod for the treatment of IBS and chronic constipation in adults and adolescents aged 12 years and above.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE 1966-December 2006 and EMBASE 1980 to December 2006 were searched. The text and key words used included "tegaserod", "HTF 919", "irritable bowel", "constipation" and "colonic diseases, functional". The Cochrane Central Register of Controlled Trials, and the Inflammatory Bowel Disease Review Group Specialized Trials Register were also searched. Searches stopped on 15th December 2006. Relevant articles were retrieved, and their reference lists were also reviewed. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised or quasi-randomised controlled trials comparing tegaserod with placebo, no treatment or any other intervention (pharmacological or non-pharmacological) in subjects aged 12 years and above with a diagnosis of IBS or chronic constipation, focusing on clinical endpoints were considered for review. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Study inclusion and exclusion, data extraction and quality assessment was undertaken by two authors independently. Meta-analysis was performed where study populations, designs, outcomes, and statistical reporting allowed combination of data in a valid way, using the summary statistics relative risk for dichotomous data and weighted mean difference for continuous data, both with 95% CI. Thirteen short-term placebo-controlled studies fulfilled the inclusion criteria. These were predominantly conducted in women. Ten studies evaluated the efficacy of tegaserod on global gastrointestinal (GI) symptoms in patients with constipation-predominant IBS (C-IBS). One small study evaluated safety in patients with diarrhoea-predominant IBS. Two studies evaluated the effectiveness of tegaserod for the treatment of chronic constipation.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>In patients with C-IBS, the relative risk (RR) of being a responder in terms of global relief of GI symptoms during the last 4 weeks of treatment was significantly higher with both tegaserod 12 mg and 4 mg doses compared with placebo. Although the pooled results indicate statistically significant benefit with tegaserod, the a priori minimal clinically important differences set in two of three studies were not reached. The responder rate for this endpoint was also higher when considered for the first 4 weeks of treatment (tegaserod 12 mg only). Tegaserod did not significantly improve the patients' individual symptoms of abdominal pain and discomfort although bowel habit showed a statistically significant improvement with tegaserod 4 mg and there was a non-significant trend in this outcome in favour of tegaserod 12 mg. In patients with chronic constipation, the RR of being a responder in terms of complete spontaneous bowel movements per week with tegaserod 12 mg was 1.54 (95% CI 1.35 to 1.75), WMD for this endpoint compared with placebo 0.6 (95% CI 0.42 to 0.78). Differences between tegaserod and placebo in increases in frequency of bowel movements were small (less than one per week). The proportion of patients with either diagnosis who experienced diarrhea was significantly higher in the tegaserod 12 mg group compared with placebo (RR 2.80, 95% CI 2.13 to 3.68), with a number needed to harm (NNH) of 20. Effects of tegaserod on GI symptoms such as bloating, stool consistency, and straining were not consistent across the studies. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Tegaserod appears to improve the overall symptomatology of IBS, and the frequency of bowel movements in those with chronic constipation. The clinical importance of these modest improvements is not clear. There are currently few data on its effect on quality of life. In addition, more information is needed about its efficacy in men. It would also be of interest to know whether treatment with tegaserod leads either directly, or indirectly, to changes in visceral sensitivity or psychopathology, which are also considered important in the pathophysiology of these conditions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Irritable bowel syndrome (IBS) is a chronic, relapsing condition (<LINK REF="REF-Talley-2002" TYPE="REFERENCE">Talley 2002</LINK>), characterised by the presence of abdominal pain and disturbed bowel habit. Symptoms of IBS sometimes overlap with other functional gastrointestinal (GI) disorders such as non-ulcer dyspepsia (<LINK REF="REF-Jones-2000" TYPE="REFERENCE">Jones 2000</LINK>). Irritable bowel syndrome may also co-exist with organic GI pathology, but whilst many of the symptoms are similar in nature, some occur more commonly in IBS such as easing of pain after bowel movement, looser stools and/or more frequent bowel movements at onset of pain, abdominal distension, and a feeling of incomplete emptying (<LINK REF="REF-Farthing-1998" TYPE="REFERENCE">Farthing 1998</LINK>). </P>
<P>Although symptoms of the GI tract predominate in IBS, non-GI symptoms are frequent and support the diagnosis. These symptoms include lethargy, poor sleep, backache, urinary frequency, and dyspareunia (<LINK REF="REF-Jones-2000" TYPE="REFERENCE">Jones 2000</LINK>). About 40 to 60% of patients who seek medical advice have evidence of psychopathology (<LINK REF="REF-Farthing-1998" TYPE="REFERENCE">Farthing 1998</LINK>).</P>
<P>The pattern of symptoms varies between individuals. Many patients have mild symptoms on an intermittent basis, and do not request or require drug treatment. Others can be incapacitated with persistent symptoms and seek medical advice, expecting a permanent cure (<LINK REF="REF-Farthing-1998" TYPE="REFERENCE">Farthing 1998</LINK>). Difficulty in confirming the diagnosis may lead to increased worry and doubt. A further burden, especially in women, is the risk of unnecessary surgery such as cholecystectomy or hysterectomy, which may aggravate the existing disorder, and cause post-operative complications such as adhesions, and surgery-related changes in bowel habit (<LINK REF="REF-Jones-2000" TYPE="REFERENCE">Jones 2000</LINK>).</P>
<P>A variety of factors lead to presentation in patients with IBS. These vary in nature, e.g. from stress to precipitation by infection. Although the cause of IBS is unknown, the following pathophysiological factors have been implicated (<LINK REF="REF-Farthing-1995" TYPE="REFERENCE">Farthing 1995</LINK>):<BR/>
</P>
<UL>
<LI>disordered motility (small intestine, colon, oesophagus, and stomach);</LI>
<LI>disordered sensation (visceral hypersensitivity); and</LI>
<LI>central nervous system changes e.g. perception.</LI>
</UL>
<P>
<BR/>The diagnosis of IBS is clinically based, relying on history taking, physical examination, and where necessary, exclusion of other GI pathology. Diagnostic criteria (e.g. Manning, Rome [I, II and III]) have been introduced to aid this process, and are widely used for identifying and recruiting patients into clinical studies of interventions for IBS (<LINK REF="REF-Camilleri-2001" TYPE="REFERENCE">Camilleri 2001</LINK>; <LINK REF="REF-Hammer-1999" TYPE="REFERENCE">Hammer 1999</LINK>). However, they are probably not used so often in clinical practice.</P>
<P>The aims of treatment in IBS are to improve the quality of life of patients, reduce the number of workdays missed through ill health, and to reduce the frequency of physician visits for both GI and non-GI related reasons (<LINK REF="REF-Jones-2000" TYPE="REFERENCE">Jones 2000</LINK>). The mainstays of treatment are explanation and reassurance regarding the nature of the condition, together with appropriate lifestyle adjustments such as dietary interventions, review of current medication, and evaluation of factors that precipitate symptoms. Drug therapy may benefit some patients although current treatments have limited value, with specific benefits being seen in a limited proportion of patients. Drug treatment of IBS can be considered in two categories (<LINK REF="REF-Farthing-1998" TYPE="REFERENCE">Farthing 1998</LINK>): (i) treatment aimed predominantly at the gut, targeting specific dominant symptoms, using bulking agents, motility agents, and antispasmodics; and (ii) centrally acting agents (e.g. antidepressants). The site of action of antidepressants in IBS is not entirely clear.</P>
<P>Chronic constipation is also a common gastrointestinal complaint which clinically frequently resembles constipation predominant IBS.</P>
<P>Stimulation of colonic motility may be of benefit in IBS patients whose predominant symptoms are constipation-related, or in those with chronic constipation. Tegaserod (trade names Zelnorm and Zelmac) is a selective partial 5HT<SUB>4</SUB> agonist that activates peristalsis in the smooth muscle of the GI tract accelerating gut transit. Tegaserod is an oral preparation that has been licensed for use in over 30 countries world-wide including Australia, Canada, Switzerland, the United States of America, and several Latin American countries. However in March 2007 the Food and Drug Administration (FDA) requested that the marketing of tegaserod be suspended in the USA and Canada due to safety concerns as a result of an increased rate of ischaemic cardiovascular events in patients treated with the drug (<LINK REF="REF-FDA-2007a" TYPE="REFERENCE">FDA 2007a</LINK>). Subsequently in July 2007, the FDA announced that restricted use of tegaserod will be permitted for patients who qualify within a given protocol (<LINK REF="REF-FDA-2007b" TYPE="REFERENCE">FDA 2007b</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this systematic review was to evaluate the efficacy and tolerability of tegaserod for the treatment of IBS and chronic constipation in adults and adolescents aged 12 years and above.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised or quasi-randomised controlled trials comparing tegaserod with placebo, no treatment or any other intervention (pharmacological or non-pharmacological) were included.</P>
<P>Studies were not excluded on the basis of publication status.</P>
<P>Trials were excluded if they were: studies that only administered one dose of tegaserod e.g. healthy volunteer studies; multi-dose studies that were purely pharmacokinetic; non-randomised studies. Additionally, studies conducted in children under the age of 12 years, and studies reporting only non-clinical outcomes were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults and adolescents (both genders) with a diagnosis of:<BR/>
</P>
<UL>
<LI>irritable bowel syndrome according to any predefined/specified diagnostic criteria (e.g. Manning, Rome [I, II, III]); or</LI>
<LI>chronic constipation.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials were included if one arm of the trial received tegaserod (HTF 919), which was compared with placebo, no treatment or any other intervention (pharmacological or non-pharmacological).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>It has been recommended that the primary outcome measure in clinical trials of interventions in IBS should be some form of global assessment (<LINK REF="REF-van-Zanten-1999" TYPE="REFERENCE">van Zanten 1999</LINK>). This recommendation has been adopted by the USA and European drug licensing authorities. Secondary outcomes should include a record of symptoms, and quality of life. In this review the outcomes focused on for both IBS and chronic constipation are as follows.</P>
<P>Main outcome measures:<BR/>Effect of treatment on<BR/>1) quality of life; and<BR/>2) gastrointestinal symptoms; both global assessment and individual symptoms including abdominal pain, distension (bloating), flatulence, bowel disturbance, constipation, diarrhoea, stool frequency, and stool consistency.</P>
<P>Other outcome measures:<BR/>3) Patient's compliance with treatment;<BR/>4) Adverse effects; and<BR/>5) Withdrawal (rebound) effects following discontinuation of treatment.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The literature search aimed to locate randomised controlled trials.</P>
<P>Electronic searches of the following databases were conducted:<BR/>
</P>
<UL>
<LI>MEDLINE (ovid 1966 to 2006)</LI>
<LI>EMBASE (ovid 1980 to 2006)</LI>
<LI>The Cochrane Central Register of Controlled Trials (the former Cochrane Controlled Trials Register)</LI>
<LI>The Cochrane Inflammatory Bowel Disease Review Group Specialized Trials Register</LI>
<LI>The USA Food and Drug Administration (http://www.fda.gov)</LI>
</UL>
<P>
<BR/>Search terms used in MEDLINE included the following list of Index terms and text words, which were adapted for use with other databases:<BR/>Index terms (MESH): colonic diseases, functional; serotonin agonist$<BR/>Text words: irritable bowel; irritable bowel syndrome; constipation; tegaserod; HTF 919; zelmac; zelnorm; 5HT; 5HT4</P>
<P>An RCT filter was applied to the electronic searches. The searches were limited to humans. No restrictions were applied with regard to language of publication or participants' age. It was our intention to translate trials reported in foreign languages; one such paper is awaiting assessment. Electronic searches were stopped on 15th December 2006. Studies identified after this date and which were considered appropriate were still assessed for eligibility.</P>
<P>Conference proceedings from (1) the British Society of Gastroenterology Annual Meeting (held in March), and (2) the Digestive Disease Week (the annual meeting of the American Gastroenterological Association, held in May) were searched from 1998 to 2006. Further information on unpublished studies and studies published only as abstracts was sought from the manufacturer Novartis. Reference lists from included trials were scanned to identify additional trials. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Methods adhered to the guidance laid out in the Cochrane Reviewer's Handbook 4.1.4. Study selection, quality assessment and data extraction were undertaken independently by two authors (BWE, WKC). Disagreements were resolved by discussion with referral to a third author if differences could not be resolved (DJM). </P>
<P>Quality assessment considered the four following criteria: selection, performance, attrition, and detection biases (as described in the Cochrane Reviewers' Handbook). Based on these criteria, studies were subdivided into one of three broad categories:<BR/>i. Low risk of bias (plausible bias unlikely to seriously alter the results; all quality criteria met); <BR/>ii. Moderate risk of bias (plausible bias that raises some doubt about the results; one or more criteria partly met); and<BR/>iii. High risk of bias (plausible bias that seriously weakens confidence in the results; one or more criteria not met).</P>
<P>Data extraction was undertaken using a data extraction form, which collected information on study methods, participants, interventions, outcome measures, and results. </P>
<P>Data synthesis was considered where the study populations, designs, outcomes and statistical reporting allowed combination of data in a valid way. Statistical heterogeneity was explored using the Chi square test with significance set at P &lt; 0.10. Provided statistical heterogeneity was not present (P &gt; 0.10), a fixed effects model was used for the analyses. If heterogeneity was present, possible sources would be investigated. The summary statistic for dichotomous data was the relative risk (RR), with 95% confidence intervals quoted. The summary statistic for continuous data was weighted mean difference (WMD). The analyses included all randomised participants in the treatment groups to which they had been allocated. Restricted analyses (excluding any unpublished studies, studies published in abstract form, studies enrolling patients using different diagnostic criteria, quasi-randomised studies) were performed where appropriate.</P>
<P>The analyses were conducted using review manager (RevMan) 4.2.8 software.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>A total of thirteen RCTs, identified from twenty-two publications, met the inclusion criteria (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). Twelve of the studies were placebo-controlled. One evaluated the addition of tegaserod to a laxative compared to a laxative alone (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>).</P>
<P>Four studies investigating tegaserod use in patients with IBS were excluded (<LINK REF="STD-Bardhan-2004" TYPE="STUDY">Bardhan 2004</LINK>; <LINK REF="STD-Tougas-2002" TYPE="STUDY">Tougas 2002</LINK>; <LINK REF="STD-Appel_x002d_Dingemanse" TYPE="STUDY">Appel-Dingemanse</LINK> 2000; <LINK REF="STD-Prather-2000" TYPE="STUDY">Prather 2000</LINK>). One was a non-randomised study, two RCTs reported non-clinical outcomes only, and one randomised study had no control group (See Table of characteristics of excluded studies).</P>
<P>Of the thirteen RCTs that met the inclusion criteria, nine studies were reported as fully published papers. Data from three studies were published in abstracts (<LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>), and in information provided in the Briefing Document submitted by the manufacturers to the Federal Drug Administration (FDA) in 2000 (<LINK REF="REF-Novartis-2000" TYPE="REFERENCE">Novartis 2000</LINK>). No publications of the remaining study, <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>, were identified other than the information provided in the FDA Briefing Document (<LINK REF="REF-Novartis-2000" TYPE="REFERENCE">Novartis 2000</LINK>). Further information on the trials published only as abstracts and the unpublished study (<LINK REF="STD-B307" TYPE="STUDY">B307</LINK>) was sought from the manufacturers (USA contact), but none was received.</P>
<P>Ten studies were conducted in a total of 8,589 patients with constipation-predominant IBS (C-IBS) (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). C-IBS was diagnosed using the Rome criteria; Rome I in six studies (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>), and Rome II in four (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>). Two studies enrolled a total of 2612 patients with chronic constipation, defined as an average of fewer than three complete spontaneous bowel movements per week, together with at least one of the following symptoms occurring at least 25% of the time: straining, incomplete evacuation, very hard and/or hard stools (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). One study was conducted in 86 patients with diarrhoea-predominant IBS (D-IBS), based on Rome I diagnostic criteria (<LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>). </P>
<P>The population studied was predominantly women (refer to Table of included studies). Two studies enrolled only women (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>). Reported age of patients in treatment groups of the included studies ranged from a mean of approximately 36 years to 48 years (see Table of included studies), except for the study evaluating tegaserod in combination with a laxative which was undertaken in adolescents with mean age 15 years (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>). </P>
<P>The duration of C-IBS in studies including adults varied, ranging from means of 7.2 to 17.4 years (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>) or medians of 8.2 to 10.0 years (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). Mean duration of C-IBS in the adolescents evaluated was 7 months (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>). The duration of constipation in the two studies that evaluated this condition was 15 years (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>) and 19 years (<LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). </P>
<P>To qualify for enrolment several studies specified a minimum duration of symptoms of 3 months (<LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>) or 6 months (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). Patients also had to fulfill certain symptom criteria in most of the studies. In four C-IBS studies, patients were required to have two of three constipation criteria, which were fewer than 3 bowel movements per day, hard or lumpy stools, or straining at least 25% of the time (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). Another C-IBS study required that patients had C-IBS and abdominal/pain with at least two other symptoms for at least 12 weeks during the previous 12 months, and had used non-drug therapy for at least 2 months without adequate relief of their symptoms (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>). Patients in the <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK> study were required to have two of three diarrhoea criteria, which were more than 3 bowel movements per day, loose or watery stools, or urgency at least 25% of the time. Refer to the Table of included studies for more information.</P>
<P>Exclusion criteria were listed in the fully published studies. Patients were generally excluded if they had organic bowel disease; were planning to use drugs that affect GI motility and/or perception; had cathartic colon, or other conditions known to affect bowel transit (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). </P>
<P>Study design<BR/>Of the ten studies evaluating tegaserod for the treatment of C-IBS, two were phase II dose-finding studies (<LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>), which evaluated daily doses of 1 mg, 4 mg, 12 mg, and 24 mg of tegaserod. Three (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>) were the original phase III studies of the tegaserod clinical trial programme. Of these, <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK> and <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> were identical in design, evaluating two fixed daily doses of 4 mg and 12 mg. <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> was also similar in design except that the tegaserod 12 mg treatment arm started with a dose of 4 mg, which could be increased to 12 mg according to response (the dose was increased from 4 mg to 12 mg in 65% of patients after the first month of double-blind treatment). The remaining five studies in C-IBS (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>) evaluated the 12 mg dose of tegaserod only. Each of the studies was short-term with treatment periods of between 4 and 12 weeks. This was preceded by treatment-free periods of 2 or 4 weeks, and in three studies, was followed by a 4-week withdrawal period (<LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>). <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> considered the effectiveness of repeated tegaserod treatment in patients who had responded to the first course of tegaserod (those with at satisfactory relief of their overall symptoms or of abdominal pain and discomfort at least 50% of the time), but who experienced recurrence of symptoms after treatment withdrawal. </P>
<P>Both studies of tegaserod for chronic constipation evaluated 4 mg and 12 mg doses for 12-week double-blind treatment periods (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). One of the studies also had a 4-week withdrawal period (<LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>).</P>
<P>In the D-IBS population studied by <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>, 8 weeks' treatment with 4 mg and 12 mg daily doses of tegaserod was evaluated. </P>
<P>All daily doses of tegaserod across all trials were taken in two divided doses.</P>
<P>OUTCOMES</P>
<P>Patients recorded their IBS symptoms in paper diaries (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>), in an electronic diary (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>), or using a touch tone telephone system (<LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>).</P>
<P>C-IBS <BR/>Nine studies that enrolled patients with C-IBS evaluated a global outcome (Subjects Global Assessment [SGA]) encompassing GI symptoms (SGA of Relief, or SGA of GI symptoms). The question asked of patients in order to determine the proportion of responders for these endpoints differed among the studies. In the dose-ranging tegaserod studies (<LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>) patients were asked, "Compared to the way you usually felt during the 3 months before you entered the study, are your overall GI symptoms over the past 4 weeks completely, considerably, somewhat relieved, unchanged or worse"? Patients with complete or considerable relief at study endpoint (last 4 weeks of treatment) were called responders.</P>
<P>
<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>, <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>, <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> and <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> asked patients, "Please consider how you felt this past week in regard to your IBS, in particular your overall well-being, and symptoms of abdominal discomfort, pain and altered bowel habit. Compared to the way you usually felt before entering the study, how would you rate your relief of symptoms during the past week"? Possible answers were: completely relieved, considerably relieved, somewhat relieved, unchanged, or worse. Patients with complete or considerable relief at least 50% of the time, or with somewhat relief 100% of the time at study endpoint were called responders (the study endpoint was defined as the last 4 available weekly SGA scores, or all weekly SGA scores if fewer than 4 were available).</P>
<P>
<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>, <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK> and <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK> asked, "Over the past week do you consider that you have had satisfactory relief from your IBS symptoms" over the first four weeks of double-blind treatment. Patients answered yes or no. Patients with at least 75% (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>) or 50% (<LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>) of 'yes' responses were called responders. </P>
<P>Three of these studies also specified what they considered to be a minimal clinically important difference in the proportion of responders for SGA of Relief between treatments (<LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). Refer to the table of included studies. </P>
<P>Other outcomes reported in these studies were patients' assessment of:<BR/>
</P>
<UL>
<LI>abdominal pain and discomfort (7 studies; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>);</LI>
<LI>bowel habit (4 studies; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> - This endpoint encompassed intensity of abdominal discomfort/pain; intensity of abdominal bloating; number of bowel movements; and average daily stool consistency);</LI>
<LI>satisfaction with bowel habit (1 study; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>);</LI>
<LI>constipation (3 studies; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>; <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>);</LI>
<LI>GI symptoms such as bloating, bowel movements (7 studies; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>); and</LI>
<LI>quality of life (Work Productivity and Activity Impairment questionnaire for IBS) - 1 study (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; data were reported in a separate paper [<LINK REF="STD-Reilly-2005" TYPE="STUDY">Reilly 2005</LINK>]).</LI>
</UL>
<P>
<BR/>
<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK> considered the effectiveness of adding tegaserod to laxative treatment in terms of abdominal pain and bowel movements per week.</P>
<P>Chronic constipation<BR/>Both studies evaluated the same outcomes; the responder rate for complete spontaneous bowel movements (CSBM, defined as an increase of one or more CSBM per week), changes in frequency of bowel movements, time to first CSBM, stool form, and laxative use (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). Changes in other symptoms were also reported; sensation of complete evacuation, straining, and global measures (bothersomeness of constipation, abdominal bloating/distension, and satisfaction with bowel habit).</P>
<P>D-IBS<BR/>
<LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK> focussed on safety and tolerability of tegaserod with respect to effects on GI symptoms (e.g. number of bowel movements, days with loose or watery stools, and stool consistency score).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Quality assessment of only the fully published studies was performed, as there was insufficient information to assess the quality of the studies published in abstract form. All studies were described as randomised. Six studies described the method of randomisation (<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>; <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>). Allocation of treatment was concealed in three studies (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>) but this was unclear in the remainder. Using the Cochrane criteria for selection, performance, detection, and attrition bias, studies with adequate allocation concealment had low risk of selection bias (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>) whereas others had at least moderate risk of bias.</P>
<P>Performance and detection bias was possible in all studies. Although five of the studies stated that tegaserod and placebo tablets were identical in appearance (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>), or that double-dummy blinding was used (<LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>), it is unclear whether personnel providing care and/or assessing outcomes were blind to assigned treatment. Two studies report that all personnel were blinded to assigned treatment (<LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>). The method of blinding is not explained in <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>. Treatment was not blinded in <LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>. Attrition bias is unlikely as each study used intention to treat (ITT) analysis, stated all withdrawals and the reasons for withdrawals, with the exception of <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK> where only withdrawals due to adverse events were listed.</P>
<P>In all but <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK> the treatment groups within each study were comparable at baseline. There are concerns regarding the comparability of the treatment groups at baseline in the <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK> study. The mean number of bowel movements per week, (P &lt; 0.02) and the mean number of days with 4 or more bowel movements per week, (P &lt; 0.05) were significantly higher in the placebo group than either of the tegaserod groups (4 mg and 12 mg). This may introduce considerable bias in view of the small size of the study (n = 86).</P>
<P>In 12 studies the study sponsor was the manufacturer, Novartis. The <LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK> study received no external funding.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>C-IBS<BR/>SGA OF RELIEF<BR/>Data from four studies that compared tegaserod 12 mg with placebo (n = 3194) and reported responder rates for the last 4 weeks of double-blind (DB) treatment were combined (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). Individually, of the four studies, statistically significant benefit was apparent in two (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>), with a non-significant trend for benefit with tegaserod seen in the other two (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>); see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. The Chi square test indicated no significant heterogeneity between the four studies. Therefore, the fixed-effects model was used in the meta-analysis. The RR for being a responder in terms of SGA of Relief at endpoint with tegaserod 12 mg compared with placebo was 1.19 (95% CI 1.09 to 1.29), indicating statistically significant benefit. The risk difference (RD) for this comparison was 0.07 (95% CI 0.03 to 0.10), with a number needed to treat (NNT) of 14. When a restricted analysis was performed, combining data from the two fully published studies, the RR was 1.16 (95% CI 1.04 to 1.29) indicating statistically significant benefit. The RD for this comparison was 0.06 (95% CI 0.02 to 0.10), with a NNT of 17. </P>
<P>Complete numerical results were not reported for each treatment group in the publications of <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK> and <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK>. </P>
<P>For the comparison of tegaserod 4 mg with placebo, data from three studies (n = 1685) were pooled (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). Of the three studies, a statistically significant benefit was apparent in one (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>), and a non significant trend in favour of tegaserod in the other two (<LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). The pooled data show that the RR of SGA of Relief at endpoint for tegaserod 4 mg compared with placebo was 1.15 (95% CI 1.02 to 1.31), indicating statistically significant benefit. The RD for this comparison was 0.05 (95% CI 0.01 to 0.10), with a NNT of 20. The same three studies compared 12 mg and 4 mg tegaserod doses (n = 1682). Pooled data from these were non-significant, RR 1.09 (95% CI 0.97 to 1.22).</P>
<P>When all tegaserod doses were combined and compared with placebo (n = 4040), the RR of being a responder at endpoint was 1.17 (95% CI 1.08 to 1.27), indicating statistically significant benefit (<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>). The RD was 0.06 (95% CI 0.03 to 0.09), with a NNT of 17. Although the pooled results indicate statistically significant benefit with tegaserod, the a priori minimal clinically important differences set by <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> and <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK> in their studies were not reached. </P>
<P>Data from two other studies that used a different definition of responder and at a different time point (weeks 1-4 of DB treatment) were pooled separately (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>). The RR for being a responder in terms of SGA of Relief for weeks 1-4 of DB treatment with tegaserod 12 mg compared with placebo was 1.46 (95% CI 1.28 to 1.66), indicating statistically significant benefit. The RD for this comparison was 0.12 (95% CI 0.08 to 0.16), with a NNT of 8 (n = 3180). The results for the <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK> study met the pre-defined criteria for a minimal clinically important difference between groups. </P>
<P>ABDOMINAL PAIN AND DISCOMFORT<BR/>Three studies reported responder rates, which were combined in a meta-analysis for both 12 mg and 4 mg doses vs placebo (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>); see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. A responder was a patient who fulfilled the adjustment rules and the following criteria: at least 20 mm and 40% reduction in mean VAS score at endpoint compared to baseline. Individually, the three studies showed disparate results with <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> suggesting no benefit with either tegaserod dose, and <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>and <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> showing a non-significant trend in favour of tegaserod (both doses). Due to the significant heterogeneity among the studies, a random-effects model was used in the meta-analysis. The RR for being a responder with tegaserod 12 mg compared with placebo (n = 1675) was 1.16 (95% CI 0.89 to 1.51), and 1.10 (95% CI 0.82 to 1.49) for tegaserod 4 mg compared with placebo (n = 1685). Both results show a non-significant difference between tegaserod and placebo treatment. When the 12 mg and 4 mg tegaserod doses were compared (n = 1682), the results were non-significant, RR 1.05 (95% CI 0.90 to 1.23). Pooling all tegaserod doses compared with placebo (n = 2521) gave a RR of being a responder of 1.13 (95% CI 0.85 to 1.51), which was also not statistically significant.</P>
<P>The SGA of abdominal pain and discomfort was also a planned endpoint in the <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK> and <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK> studies, but no numerical data were found for the individual tegaserod groups in these studies. <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> reported mean score differences rather than responder rates, which showed significant improvement from baseline with tegaserod 12 mg compared with placebo (-1.01 vs -0.80, P &lt; 0.003).</P>
<P>
<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> reported the proportion with satisfactory relief of abdominal pain and discomfort (75% of the time) over the 4-week treatment period. The difference between tegaserod 12 mg and placebo groups was statistically significant (9.1%, 95% CI 5.2 to 13.0). The proportion of patients reporting improvement in these symptoms (of one point or more on a 7-point scale) was also higher with tegaserod than placebo (52.5% vs 42.8%, P &lt; 0.001).</P>
<P>
<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK> considered abdominal pain on a scale of 0-10 (none to worse possible); see <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>. The mean pain score was lower with combined tegaserod and laxative treatment than with laxative alone at 4 weeks (4.29 vs 6.15, P &lt; 0.05). The proportion of patients with good pain reduction (defined as a reduction in pain score of 3 or more points compared with pre-treatment) was also higher with combination treatment (66.7% vs 18.5%, P &lt; 0.05).</P>
<P>BOWEL HABIT <BR/>Three studies reported responder rates, which were combined in a meta-analysis for both 12 mg and 4 mg doses vs placebo (<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>; <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK>; <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>); see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. A responder was a patient who fulfilled the adjustment rules and the following criteria: at least 20 mm and 40% reduction in mean VAS score at endpoint compared to baseline. Individually, of the three studies, <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> suggested no benefit with either tegaserod dose, and <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK> and <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> showed a non significant trend in favour of tegaserod (both doses). No statistically significant heterogeneity was detected. Pooled data from three studies (n = 1685) indicate that patients treated with tegaserod 4 mg were significantly more likely than placebo to be responders, RR 1.21 (95% CI 1.03 to 1.43). The RD for this comparison was 0.05 (95% CI 0.01 to 0.09), with a NNT of 20. The RR for tegaserod 12 mg compared with placebo (n = 1675) was non-significant, 1.10 (95% CI 0.93 to 1.31). When both tegaserod doses were compared, the result was non-significant, RR 0.91 (95% CI 0.78 to 1.07). When all tegaserod doses were pooled and compared with placebo (n = 2521), the RR of being a responder was 1.16 (95% CI 1.00 to 1.34) which does not indicate statistical significance. </P>
<P>
<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> reported the mean score difference from baseline to endpoint on a 7-point ordinal scale, which was reduced to a significantly greater extent with tegaserod 12 mg compared with placebo (-1.30 vs -0.95, P &lt; 0.001). </P>
<P>SATISFACTION WITH BOWEL HABIT<BR/>
<LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> reported response rates at months one, two and three (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). A responder was a patient who was 'very satisfied' or 'somewhat satisfied' at 50% of assessments. The response rates at all time points were significantly higher in the tegaserod 12 mg group than with placebo.</P>
<P>CONSTIPATION<BR/>Constipation was a planned endpoint in four studies. <LINK REF="STD-Hamling-1998" TYPE="STUDY">Hamling 1998</LINK> reported responder rates but not for the ITT population, and only for pooled tegaserod groups. A responder was a patient with considerable or complete relief at study endpoint (last 4 weeks of treatment). No numerical data were presented for this endpoint in the publications related to <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK>.</P>
<P>
<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> reported the proportion with satisfactory relief of constipation (75% of the time), which was higher with tegaserod 12 mg than placebo (39.4% vs 25% respectively, P &lt; 0.001).</P>
<P>
<LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK> reported the change in frequency of bowel movements per week. This was higher following combined tegaserod and laxative treatment than with laxative alone at 4 weeks (mean frequency 6.57 vs 5.04, P &lt; 0.05). </P>
<P>OTHER GI SYMPTOMS<BR/>
<LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>, <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> and <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> recorded changes in bloating, abdominal pain/discomfort, bowel movements and stool consistency. The number of days without bowel movements was reduced and the number of bowel movements increased significantly with tegaserod 12 mg compared with placebo. There was a non-significant trend towards reduction in days with significant abdominal pain and discomfort, days with significant bloating, and days with hard or very hard stools in both tegaserod groups compared with placebo. <LINK REF="STD-Lefkowitz-1999a" TYPE="STUDY">Lefkowitz 1999a</LINK> reported scores for days with pain, bloating, and bowel movements according to whether they were deemed to be responders, not by treatment group.</P>
<P>
<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>, <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>, <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK> and <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> also reported results for some individual GI symptoms. Data from the studies were not pooled because although apparently similar the outcomes were not consistently defined, nor were they measured across the same treatment weeks. <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> reported statistically significant differences forimprovements in bloating and stool consistency in favour of tegaserod. <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK> reported that days with hard or very hard/lumpy stools were significantly fewer with tegaserod 12 mg compared with placebo and days with loose or watery stools higher. There were no significant differences identified between groups in bloating or days with at least moderate abdominal pain or discomfort. Days with straining and a sensation of incomplete evacuation were significantly reduced with tegaserod 12 mg compared with placebo; days with urgency were significantly reduced with tegaserod during weeks 1-4 but not weeks 9-12 (<LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>).</P>
<P>
<LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK> reported that days with hard or lumpy stools and days with at least moderate abdominal pain and discomfort were significantly fewer with tegaserod 12 mg compared with placebo, with no significant differences identified between groups in bloating, number of bowel movements, stool consistency, urgency, or straining. In the <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK> study, the number of bowel movements increased significantly, and bloating, straining, and stool consistency scores fell significantly with tegaserod 12 mg from baseline compared with placebo.</P>
<P>QUALITY OF LIFE<BR/>
<LINK REF="STD-Reilly-2005" TYPE="STUDY">Reilly 2005</LINK> reported results of the Work Productivity and Activity Impairment questionnaire for IBS in the 63% of patients included in the <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> study who were employed. Only data for the first 4-week treatment period are available. These show reductions with tegaserod 12 mg compared with placebo of 2.6% in absenteeism (P = 0.004), 5.4% in presenteeism (P &lt; 0.0001), 6.3% in work productivity loss (P &lt; 0.0001), and 5.8% in daily activity impairment (P &lt; 0.0001).</P>
<P>REPEAT TREATMENT<BR/>In the <LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK> study, statistically significant benefit for all GI outcomes was reported in patients who had a second course of tegaserod treatment compared with placebo (see <LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>).</P>
<P>
<B>Chronic constipation studies</B>
<BR/>Both of the chronic constipation studies reported the responder rate for complete spontaneous bowel movements (CSBM, defined as an increase of one or more CSBM per week) following 12 weeks treatment; see <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>. Data were combined for the tegaserod 12 mg group compared with placebo (n = 1745). The RR of responding to tegaserod 12 mg was 1.54 (95% CI 1.35 to 1.75), which indicates a statistically significant benefit. The RD for this comparison was 0.15 (95% CI 0.11 to 0.20), giving a NNT of 7 to have a mean increase of one bowel movement per week. Only <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK> reported data for the 4 mg dose at 12 weeks which showed a significantly higher responder rate than for placebo. <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK> reported that the difference between tegaserod 4 mg and placebo was not statistically significant, but did not report the responder rates. </P>
<P>Weekly bowel frequency (CSBM, spontaneous bowel movements, and bowel movements) increased in both tegaserod groups and the placebo groups. The difference between tegaserod 12 mg and placebo was statistically significant for CSBM (WMD [fixed effects] 0.6, 95% CI 0.42 to 0.78); SBM (WMD 0.91, 95% CI 0.59 to 1.23); and for bowel movements (WMD 0.75, 95% CI 0.46 to 1.05). The difference between tegaserod 4 mg and placebo were also statistically significant for CSBM (WMD [fixed effects] 0.44, 95% CI 0.26 to 0.62); SBM (WMD 0.73, 95% CI 0.41 to 1.05); and for bowel movements (WMD 0.58, 95% CI 0.28 to 0.88). Differences between tegaserod 12 mg and tegaserod 4 mg were not statistically significant. </P>
<P>Other GI symptoms<BR/>Several other outcomes were reported in both studies, the results of which are all of questionable clinical significance (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>). The median time to first CSBM was significantly shorter with tegaserod 4 mg and 12 mg than with placebo (see <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>). Stool form changed significantly in the direction of unformed stools with tegaserod compared with placebo but changes were less than one point on an 8-point scale. There was a trend towards greater reduction in straining scores (measured on a 3-point scale), and in days with too much straining. </P>
<P>The proportion of days per week when laxatives were used was less (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>) - absolute difference 0.2 days (tegaserod 4 mg) and 0.5 (tegaserod 12 mg) compared with placebo. <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK> measured the use of rescue laxative medication; differences between groups were not significantly different (absolute differences 0.1 and 0 for tegaserod 4 mg and 12 mg compared with placebo respectively).</P>
<P>Bothersomeness of constipation, abdominal bloating/distension, or abdominal pain/discomfort were measured on a 5-point scale (none to a very great deal); scores fell in all groups. No score change was greater than 0.7 although the differences were statistically significant in favour of both tegaserod groups for these three outcomes. Satisfaction with bowel habit, also measured on a scale of 0-5, increased to a greater extent with tegaserod although none of the score changes were greater than 0.8.</P>
<P>TOLERABILITY (all studies)<BR/>Numerical data for each treatment group (ITT analysis) were reported for eight studies (<LINK REF="STD-Tack-2005" TYPE="STUDY">Tack 2005</LINK>; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). See Tables 5 to 8 (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>). </P>
<P>Data on adverse events reported in the six 12-week studies that were conducted in individuals with C-IBS or chronic constipation were pooled (<LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Nyhlin-2004" TYPE="STUDY">Nyhlin 2004</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Kellow-2003" TYPE="STUDY">Kellow 2003</LINK>; <LINK REF="STD-Novick-2002" TYPE="STUDY">Novick 2002</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). A consistent effect on diarrhoea was seen in the six studies. The RR of diarrhoea with tegaserod 12 mg compared with placebo (n = 5010) was significantly higher, 2.80 (95% CI 2.13 to 3.68). The RD for this comparison was 0.05 (95% CI 0.04 to 0.06), with a number needed to harm (NNH) of 20. The RR of diarrhoea was also higher with tegaserod 4 mg than with placebo (3 studies; <LINK REF="STD-Kamm-2005" TYPE="STUDY">Kamm 2005</LINK>; <LINK REF="STD-Johanson-2004" TYPE="STUDY">Johanson 2004</LINK>; <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>); RR 1.70 (95% CI 1.12 to 2.59), RD 0.02 (95% CI 0.00 to 0.04). Of the other pooled adverse events (from five or six of the studies), none of these occurred with a significantly higher frequency with tegaserod 12 mg although there was a trend in that direction; headache RR 1.07 (95% CI 0.92 to 1.24); abdominal pain RR 1.03 (95% CI 0.83 to 1.28); and nausea RR 1.21 (95% CI 0.93 to 1.57). </P>
<P>No adverse effects were reported in <LINK REF="STD-Khoshoo-2006" TYPE="STUDY">Khoshoo 2006</LINK>.</P>
<P>Because other GI stimulants are known to have cardiac effects, e.g. cisapride (also a 5HT4 partial agonist), the electrocardiographic effects of tegaserod were investigated in studies <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>, <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> and <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> (n = 2525) and the results have been published (<LINK REF="REF-Morganroth-2002" TYPE="REFERENCE">Morganroth 2002</LINK>). The data from these short-term studies did not identify statistically significant differences between tegaserod 4 mg or 12 mg and placebo groups in the proportion of patients with prolonged QTc intervals, or the overall frequency of electrocardiographic abnormalities. However in March 2007 the FDA requested that the marketing of tegaserod be withdrawn due to an increased rate of ischaemic cardiovascular events in patients treated with the drug, although these data are not published in other trial reports considered in this review (<LINK REF="REF-FDA-2007a" TYPE="REFERENCE">FDA 2007a</LINK>). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In individuals, predominantly women, with C-IBS tegaserod 12 mg and 4 mg significantly improved patients global assessment of IBS symptomatology compared with placebo. Tegaserod did not significantly improve patients' abdominal pain and discomfort although bowel habit showed a significant improvement with tegaserod 4 mg and there was a non-significant trend in favour of tegaserod 12 mg compared with placebo. When GI symptoms were assessed separately, those indicative of GI motility such as number of bowel movements and days without bowel movements were generally improved with tegaserod, whereas effects of treatment on symptoms such as bloating and stool consistency and straining were not consistent across the studies.</P>
<P>When used for the treatment of chronic constipation tegaserod 12 mg increased the frequency of weekly bowel movements although differences between tegaserod 12 mg and placebo groups were small. Improvements in other symptoms such as straining, bloating, and abdominal pain/discomfort were also minor.</P>
<P>In the C-IBS studies the effect of publication bias was explored using a restricted analysis of pooled SGA of Relief at endpoint data for tegaserod 12 mg vs placebo. The direction of the evidence was the same when the unpublished study (<LINK REF="STD-B307" TYPE="STUDY">B307</LINK>) and the study published as an abstract were excluded from the analysis, although the NNT was higher when the unpublished studies were excluded (NNT 17 vs 14). The comparison of the 4 mg and 12 mg doses of tegaserod did not show a clear distinction between the two doses. </P>
<P>Whilst the meta-analysis has shown a significant treatment effect with both tegaserod doses compared with placebo, such a consistent effect was not seen in the individual studies. In particular, a significant difference between tegaserod 4 mg or 12 mg and placebo groups was not observed in <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>, the results of which have not been published other than in the FDA briefing document. It should be noted that in study <LINK REF="STD-B307" TYPE="STUDY">B307</LINK>, the patients in the higher dose group started off with a dose of 4 mg, which was increased to 12 mg in 65% patients. In the <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> study, only published in abstract form, a significant difference was seen with tegaserod 12 mg compared with placebo, but not with tegaserod 4 mg. <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> was the first phase III study to be completed, which prompted a change in the definition of responder because a significant treatment effect was not seen with tegaserod compared with placebo (<LINK REF="REF-Novartis-2000" TYPE="REFERENCE">Novartis 2000</LINK>). The data listed in this review are the results of the retrospective analysis of results from the <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> study that was performed when the revised definition of responder was agreed, which reduced the threshold for response. The definition of responder is described in the outcomes section.</P>
<P>With regard to tolerability in the studies, diarrhoea occurred with a significantly higher incidence in the tegaserod 12 mg group, which is not surprising given the drug's mode of action. The balance of improving symptoms of C-IBS without causing diarrhoea may be difficult to achieve. It was not possible to pool data for the 4 mg dose as the two studies contributing the relevant data enrolled different study populations (diarrhoea-predominant IBS in <LINK REF="STD-Fidelholtz-2002" TYPE="STUDY">Fidelholtz 2002</LINK>, and constipation-predominant IBS in <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>). The other documented events (abdominal pain, headache, nausea), represent some of the typical GI and extra-intestinal symptoms of IBS. Because other GI stimulants are known to have cardiac effects, e.g. cisapride (also a 5HT<SUB>4</SUB> partial agonist), the electrocardiographic effects of tegaserod were investigated in studies <LINK REF="STD-Muller_x002d_Lissner-2001" TYPE="STUDY">Muller-Lissner 2001</LINK>, <LINK REF="STD-Lefkowitz-1999b" TYPE="STUDY">Lefkowitz 1999b</LINK> and <LINK REF="STD-B307" TYPE="STUDY">B307</LINK> (n = 2525) and the results have been published (<LINK REF="REF-Morganroth-2002" TYPE="REFERENCE">Morganroth 2002</LINK>). The data from these short-term studies did not identify statistically significant differences between tegaserod 4 mg or 12 mg and placebo groups in the proportion of patients with prolonged QTc intervals, or the overall frequency of electrocardiographic abnormalities. However in March 2007 the FDA requested that the marketing of tegaserod be withdrawn due to an increased rate of ischaemic cardiovascular events in patients treated with the drug (<LINK REF="REF-FDA-2007a" TYPE="REFERENCE">FDA 2007a</LINK>). Subsequently in July 2007, the FDA announced that restricted use of tegaserod will be permitted for patients who qualify within a given protocol (<LINK REF="REF-FDA-2007b" TYPE="REFERENCE">FDA 2007b</LINK>). The treatment investigational new drug protocol specifies that tegaserod be used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55 who meet specific guidelines. In addition to the age and gender restrictions, the protocol limits use of the drug to those with C-IBS or chronic idiopathic constipation whose physicians decide the drug is medically necessary. Patients must sign consent materials to ensure they are fully informed of the potential risks and benefits of tegaserod (<LINK REF="REF-FDA-2007b" TYPE="REFERENCE">FDA 2007b</LINK>). </P>
<P>Individuals enrolled in the IBS studies included in this review fulfilled Rome diagnostic criteria, which were originally developed in order to allow greater comparability of drug effects between studies of treatments for IBS. Although the Rome criteria are frequently used entry criteria for such clinical studies, in clinical practice, studies evaluating diagnosis of IBS in primary care have found that set diagnostic criteria were rarely used (<LINK REF="REF-Thompson-1997" TYPE="REFERENCE">Thompson 1997</LINK>) and that many patients given a diagnosis of IBS did not fulfill these criteria (<LINK REF="REF-Robinson-2001" TYPE="REFERENCE">Robinson 2001</LINK>). Rome criteria have also been criticised for not encompassing some clinical patterns seen by clinicians (<LINK REF="REF-Camilleri-2001" TYPE="REFERENCE">Camilleri 2001</LINK>), such as not taking into account postprandial exacerbation of symptoms; excluding subgroups based on predominant bowel dysfunction; and not encompassing patients in whom functional, painless diarrhoea may be associated with postprandial urgency, borborygmi, and a sense of incomplete rectal evacuation. It is difficult to determine how representative the patients enrolled in the clinical trials are of those who present in the primary care setting with symptoms of IBS.</P>
<P>IBS is a complex disorder that encompasses a wide profile of symptoms. Tegaserod appears to improve the overall symptomatology of IBS, and increase the number of bowel movements in chronic constipation, but the clinical significance of these modest changes is unclear. There are currently few data on tegaserod's effect on quality of life. In addition, more information is needed about its efficacy in men. It would also be of interest to know whether treatment with tegaserod leads either directly, or indirectly, to changes in visceral sensitivity or psychopathology, which are also considered important in the pathophysiology of this condition.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>For women with constipation-predominant IBS, tegaserod offers modest improvement of their global GI symptoms, but may not address symptoms of abdominal pain and discomfort. The treatment may be an option for short-term relief of symptoms. The FDA is permitting the restricted use of Tegaserod under a treatment investigational new drug protocol. Tegaserod may be used to treat C-IBS and chronic idiopathic constipation in women under 55 where no comparable or satisfactory alternative drug is available. The patient's physician must decide the drug is medically necessary and patients must sign a consent form indicating that they are fully informed of the potential risks and benefits of tegaserod. </P>
<P>In practice the division between constipation-predominant and diarrhoea-predominant IBS may not be clear-cut in some patients. It is not yet apparent whether there is a sub-group of women with C-IBS who may gain most benefit from tegaserod treatment.</P>
<P>For women with chronic constipation tegaserod increases bowel frequency relative to placebo although the net increase is less than one bowel movement per week.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Ongoing research aims to investigate the existence of a rebound effect on withdrawal of tegaserod, and the effects of withdrawal on symptomatic control. Longer-term studies would help determine the duration of benefit with tegaserod treatment, and its safety with prolonged use. More information on the effects of tegaserod treatment on quality of life of patients, and on medical consultation rates, as well as comparative studies of tegaserod with established IBS treatments would be valuable in defining its place in therapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-06-12 12:31:05 -0400" MODIFIED_BY="John K MacDonald">
<P>Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity.</P>
<P>Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.</P>
<P>We would like to thank corresponding authors of papers for responding promptly to enquiries related to their publications. We would also like to acknowledge the support of the editorial base of the Cochrane Inflammatory Bowel Disease Review Group who have provided support and encouragement with the development of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Whorwell's unit has previously and is currently in receipt of financial support from Novartis including funding for a randomised controlled trial of tegaserod therapy.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>BWE led and co-ordinated the review, prepared the protocol, undertook the searches for and reviewed the data on effectiveness (independently assessing its quality and extracting data) and prepared the final report.<BR/>WKC independently reviewed the effectiveness data, assessed its quality and extracted data, and provided advice on the protocol and final report.<BR/>DJM provided methodological advice and steer, and acted as third opinion in the event of disagreement between BWE and WKC. DJM also provided advice on the protocol and final report.<BR/>PJW provided clinical advice on the protocol and final report, and helped with ad hoc clinical enquiries.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-12 13:10:55 -0400" MODIFIED_BY="John K MacDonald">
<STUDIES MODIFIED="2008-06-12 13:10:55 -0400" MODIFIED_BY="John K MacDonald">
<INCLUDED_STUDIES MODIFIED="2008-06-12 13:10:55 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-B307" MODIFIED="2008-06-12 13:10:55 -0400" MODIFIED_BY="John K MacDonald" NAME="B307" YEAR="">
<REFERENCE MODIFIED="2008-06-12 13:10:55 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="OTHER">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fidelholtz-2002" NAME="Fidelholtz 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fidelholtz J, Smith W, Rawls J, Shi Y, Zack A, Ruegg P, et al</AU>
<TI>Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms</TI>
<SO>Am J Gastroenterol</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>1176-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="9270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rawls J, Lefkowitz M, Shi Y, Zack A, Dunger-Baldauf C, Ruegg PC</AU>
<TO>Tegaserod is well tolerated in diarrhea-predominant irritable bowel syndrome</TO>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47 (Suppl 3)</VL>
<PG>A217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamling-1998" MODIFIED="2008-06-12 12:48:31 -0400" MODIFIED_BY="John K MacDonald" NAME="Hamling 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hamling J, Bang CJ, Tarpila S, Stewart W, Rueegg PC</AU>
<TO>Titration regimen indicates partial 5-HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS)</TO>
<SO>Digestion</SO>
<YR>1998</YR>
<VL>59 (Suppl 3)</VL>
<PG>735 (abstract B5324)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-12 12:48:31 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="OTHER">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johanson-2004" NAME="Johanson 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Johansen JF, Tougas G, Chey WD, Novick JS, Lembo A, Fordham F, Guella MP, Nault B</AU>
<TI>Tegaserod provides rapid and sustained relief of constipation, abdominal bloating/distension, and abdominal discomfort/pain in patients with chronic constipation</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>Abs 371 (A-47)</PG>
<EN>4 (Suppl 1)</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Wald A, Tougas G, et al</AU>
<TI>Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial</TI>
<SO>Clin Gastroenterol Hepatol</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>9</NO>
<PG>796-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wald A, Johanson J, Tougas G, Chey W, Novick J, Lembo A, Fordham F, Guella M, Nault B</AU>
<TI>Safety and tolerability of tegaserod in patient treated for chronic constipation (CC): A 12 week, double-blind, placebo-controlled multicenter study performed in the Americas</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>Abs T1818 (A-573)</PG>
<EN>4 (Suppl 1)</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamm-2005" NAME="Kamm 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamm MA, Muller-Lissner S, Talley NJ et al</AU>
<TI>Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study</TI>
<SO>Am J Gastroenterol</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>362-372</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellow-2003" MODIFIED="2008-06-12 12:44:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Kellow 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-12 12:44:05 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al</AU>
<TI>An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>671-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kellow JE, Lee O, Thongsawat S, Zawawi M, Yuen H, Gwee K, et al</AU>
<TI>Tegaserod is an effective therapy for non-diarrhea irritable bowel syndrome in an Asian-Pacific population</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51 (Suppl 2)</VL>
<PG>A11 (abstract 035)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khoshoo-2006" NAME="Khoshoo 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khoshoo V, Armstead C, Landry L</AU>
<TI>Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>191-196</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefkowitz-1999a" MODIFIED="2008-06-12 12:48:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Lefkowitz 1999a" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Lefkowitz MP, Ruegg P, Shi Y, Dunger-Baldauf C</AU>
<TO>Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919</TO>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<PG>A1027 (abstract G4462)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-12 12:48:08 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Whorwell P, Muller-Lissner S, Langaker KJ, Wald A, Pruitt R, Ruegg P</AU>
<TO>Short and long-term safety and tolerability of tegaserod in patients with IBS</TO>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45 (Suppl 5)</VL>
<PG>A260 (abstract P0966)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefkowitz-1999b" MODIFIED="2008-06-12 12:49:18 -0400" MODIFIED_BY="John K MacDonald" NAME="Lefkowitz 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Krumholz S, Tanghe J, Schmitt C, Heggland J, Shi Y, Ruegg PC</AU>
<TO>The 5HT4 partial agonist, tegaserod, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS)</TO>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45 (Suppl 5)</VL>
<PG>A260 (abs P0965)</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study code B351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lefkowitz M, Shi Y, Heggland J, Dunger-Baldauf C, Ruegg PC</AU>
<TI>Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47 (Suppl 3)</VL>
<PG>A217 (abstract P833)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Lefkowitz M, Shi Y, Schmitt C, Krumholtz S, Tanghe J</AU>
<TO>The 5HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS)</TO>
<SO>Am J Gastroenterol</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>9</NO>
<PG>2676 (abstract 396)</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study code 351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-12 12:49:18 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schmitt C, Krumholz S, Tanghe J, Heggland J, Shi Y, Lefkowitz M</AU>
<TO>Tegaserod, a partial 5HT4 agonist improves abdominal discomfort/pain and altered bowel function in irritable bowel syndrome</TO>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45 (Suppl 5)</VL>
<PG>A258 (abstract P0960)</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Study code B351"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller_x002d_Lissner-2001" MODIFIED="2008-06-12 12:51:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Muller-Lissner 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-12 12:51:08 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mueller-Lissner S, Fumagalli I, Bardhan KD, Pace F, Nault B, Pecher EC, et al</AU>
<TI>Tegaserod, a 5HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>116 (Suppl 2)</VL>
<PG>A175 (abs 1000)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al</AU>
<TI>Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>1655-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7739"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-12 12:49:36 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novick-2002" NAME="Novick 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lefkowitz M, Ligozio G, Glebas K, Heggland JE</AU>
<TO>Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation</TO>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120 (Suppl 1)</VL>
<NO>Supplement 1</NO>
<PG>A22 (abstract 104)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al</AU>
<TI>A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1877-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyhlin-2004" MODIFIED="2008-06-12 12:55:34 -0400" MODIFIED_BY="John K MacDonald" NAME="Nyhlin 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-12 12:55:34 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Berge M, et al</AU>
<TI>Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>4 Suppl 1</NO>
<PG>A389</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nyhlin H, Bang C, Elsborg L, et al</AU>
<TI>A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patient with irritable bowel syndrome</TI>
<SO>Scand J Gastroenterol</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>2</NO>
<PG>119-126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reilly-2005" NAME="Reilly 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Publication of one outcome from the Tack study&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reilly MC, Barghout V, Mcburney CR, Niecko TE</AU>
<TI>Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2005</YR>
<VL>22</VL>
<PG>373-280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tack-2005" NAME="Tack 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tack J, Muller-Lissner S, Bytzer P et al</AU>
<TI>A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<PG>1707-1713</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-12 13:08:59 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Appel_x002d_Dingemanse" NAME="Appel-Dingemanse" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Appel-Dingemanse S, Rawls J, Heggland J, Campestrini J, Sechaud R</AU>
<TO>Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhoea-predominant irritable bowel syndrome</TO>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>Supplement 2</NO>
<PG>Abstract 5340</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bardhan-2004" NAME="Bardhan 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bardhan KD, Forbes A, Marsden CL et al</AU>
<TI>The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>213-222</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bardhan KD, Forbes A, Marsden CL</AU>
<TI>A clinical investigation of the effects of tegaserod treatment regimen on the symptoms of IBS-C in tegaserod-responsive patients</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>Suppl 1</VL>
<PG>Abs 053</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prather-2000" MODIFIED="2008-06-12 13:08:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Prather 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-12 13:08:59 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G</AU>
<TI>Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>463-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tougas-2002" MODIFIED="2008-06-12 13:05:18 -0400" MODIFIED_BY="John K MacDonald" NAME="Tougas 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-12 13:05:18 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tougas G, Snape WJ, Otten MH, Earnest DL, Langaker KE, Pruitt RE et al</AU>
<TI>Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome</TI>
<SO>Aliment Pharmacol Ther</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1701-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2003" NAME="Anon 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tegaserod Clinical Research Group</AU>
<TI>[A randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome] [Chinese]</TI>
<SO>Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>2</NO>
<PG>88-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chey-2006" NAME="Chey 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA</AU>
<TI>Tegaserod improves multiple symptoms in women with mixed/alternating bowel habits as well as those with IBS-C</TI>
<SO>Gastroenterology</SO>
<YR>2006</YR>
<VL>130</VL>
<NO>4</NO>
<PG>Abs 135 (A-26)</PG>
<EN>Suppl 2</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2003" NAME="Lin 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Is an RCT.&lt;br&gt;Was presented at the DDW 2003.&lt;br&gt;I was sent this by John M.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lin S, Zhou L, Xinguang L, Ke M, Wang H, Cheng L, et al</AU>
<TO>Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with irritable bowel syndrome with constipation (IBS-C)</TO>
<SO>Digestive Disease Week</SO>
<YR>2003</YR>
<PG>Abs S1017</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munoz-2003" NAME="Munoz 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;A response-mediated withdrawal study, where all patients received T to start, then those who responded were reandomised to withdraw Tx or to continue.&lt;br&gt;Data presented at DDW 2003, sent to me by John M.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Munoz VC</AU>
<TO>Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C)</TO>
<SO>Digestive Disease Week</SO>
<YR>2003</YR>
<PG>Abs T1804</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-12 13:09:55 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2008-06-12 13:09:55 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Camilleri-2001" NAME="Camilleri 2001" TYPE="JOURNAL_ARTICLE">
<AU>Camilleri M</AU>
<TI>Management of the irritable bowel syndrome</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120</VL>
<PG>652-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farthing-1995" NAME="Farthing 1995" TYPE="JOURNAL_ARTICLE">
<AU>Farthing MJ</AU>
<TI>Irritable bowel, irritable body, or irritable brain?</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farthing-1998" NAME="Farthing 1998" TYPE="JOURNAL_ARTICLE">
<AU>Farthing MJ</AU>
<TI>New drugs in the management of the irritable bowel syndrome</TI>
<SO>Drugs</SO>
<YR>1998</YR>
<VL>56</VL>
<PG>11-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2007a" NAME="FDA 2007a" TYPE="OTHER">
<TI>FDA Public Health Advisory (March 30, 2007)</TI>
<SO>www.fda.gov/cder/drug/advisory/tegaserod.htm [accessed 27.05.07]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2007b" NAME="FDA 2007b" TYPE="OTHER">
<TI>FDA permits restricted use of Zelnorm for qualifying patients</TI>
<SO>http://www.fda.gov/bbs/topcs/NEWS/2007/NEW01673.html</SO>
<YR>27/07/07</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammer-1999" NAME="Hammer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hammer J, Talley NJ</AU>
<TI>Diagnostic criteria for the irritable bowel syndrome</TI>
<SO>Am J Med</SO>
<YR>1999</YR>
<VL>107</VL>
<PG>5S-11S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2000" NAME="Jones 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jones J, Boorman J, Cann P, Forbes A, Gomborone J , Heaton K, et al</AU>
<TI>British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47 (Suppl 2)</VL>
<PG>1-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morganroth-2002" NAME="Morganroth 2002" TYPE="JOURNAL_ARTICLE">
<AU>Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M</AU>
<TI>Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects</TI>
<SO>Am J Gastroenterol</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>2321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novartis-2000" MODIFIED="2008-06-12 13:09:55 -0400" MODIFIED_BY="John K MacDonald" NAME="Novartis 2000" TYPE="OTHER">
<AU>Novartis Pharmaceuticals Corporation East Hanover, New Jersey</AU>
<TI>Zelmac (tegaserod) Advisory Committee Briefing Document</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf</SO>
<YR>2000 (accessed 18/11/2002)</YR>
<PG>1-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2001" NAME="Robinson 2001" TYPE="CONFERENCE_PROC">
<AU>Robinson A, Lee V, Thompson DG</AU>
<TI>Irritable bowel syndrome diagnosed in primary care: how many patients fulfil Rome II criteria?</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>48 (Suppl 1)</VL>
<PG>A45 (abstract 164)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talley-2002" NAME="Talley 2002" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ, Spiller R</AU>
<TI>Irritable bowel syndrome: a little understood organic bowel disease</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>555-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1997" NAME="Thompson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WG, Heaton KW, Smyth GT, Smyth C</AU>
<TI>Irritable bowel syndrome: the view from general practice</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>689-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Zanten-1999" NAME="van Zanten 1999" TYPE="JOURNAL_ARTICLE">
<AU>van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR</AU>
<TI>Design of treatment trials for functional gastrointestinal disorders</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>Suppl II</VL>
<PG>II69-II77</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-B307">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 67-centre study.<BR/>Duration: 16 weeks (4 treatment-free baseline, 12 DB treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;=18 years (85% F). Mean age (SD) 45 (13) years. C-IBS (Rome I criteria). Minimum of 3 months symptoms.<BR/>Duration of IBS (mean in months, SD) 166 (154).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=283)<BR/>Tegaserod 4-12mg (n=277)<BR/>Placebo (n=285)</P>
<P>Other permitted treatments: chronic stable treatment with fibre or bulking agents.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of Relief (responder rate).<BR/>Abdominal pain and discomfort.<BR/>Bowel habit.<BR/>GI symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No publications identified for this study. Data taken from Novartis 2000.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fidelholtz-2002">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group study.<BR/>Duration: 10 weeks (2 treatment-free baseline, 8 DB treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;18 years (67.4% F). Mean age (range 21-77 years); 41.4 T12mg, 47.3 T4mg, 48.5 Plac.<BR/>D-IBS (Rome I criteria). <BR/>Minimum of 3 months symptoms. Duration of IBS (mean, in years); 9.8 T12mg, 11.5 T4mg, 10.5 Plac.<BR/>Organic disease excluded.</P>
<P>Exclusion criteria: Significant changes in bowel habit in previous 3 months; non-IBS conditions affecting bowel transit; cathartic colon; drugs affecting GI motility and/or perception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=35)<BR/>Tegaserod 12mg (n=34)<BR/>Placebo (n=17)</P>
<P>Other permitted treatments: loperamide for diarrhoea, chronic stable doses of bulking agents or antidepressants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Safety. Adverse events. No efficacy parameters reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>At baseline number of bowel movements per week, and number of days with 4 or more bowel movements per week both significantly higher in the placebo group than the tegaserod groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamling-1998">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group dose-ranging 16-centre study.<BR/>Duration 20 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years (92% F). <BR/>Mean age 44 years.<BR/>C-IBS (Rome I criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 1mg, 4mg, 12mg, 24mg - started with 1mg, up-titrated according to clinical response (n=?)</P>
<P>Placebo (n=?)</P>
<P>Total n=123, randomised 2:1 T:P</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of GI symptoms.<BR/>Abdominal discomfort.<BR/>Constipation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Responder rates determined for each endpoint.<BR/>Abstract publication of study only.<BR/>No details of statistical or other analyses used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johanson-2004">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 105-centre study.<BR/>Duration 18 weeks (2 weeks treatment-free baseline, 12 weeks DB treatment, 4 weeks optional withdrawal).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years (90% F). <BR/>Mean age 47 years.<BR/>Constipation for 6 months or more, mean 19 years (defined as an average of less than three complete spontaneous bowel movements per week, together with at least one of the following symptoms occurring at least 25% of the time: straining, incomplete evacuation, very hard and/or hard stools).</P>
<P>Exclusion criteria: Constipation caused by a known disease of the colon, pelvic floor dysfunction, metabolic disorders, neurological disorders, or other significant disease that may have prevented patients from completing the study, use of medications that affect GI function.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=450)<BR/>Tegaserod 12mg (n=451)<BR/>Placebo (n=447)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete spontaneous bowel movements (responder rate).<BR/>Weekly number of bowel movements (including complete spontaneous, and spontaneous).<BR/>Time to first complete spontaneous bowel movement. <BR/>Stool form.<BR/>Change in other symptoms (sensation of complete evacuation, straining, bothersomeness), satisfaction, laxative use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Responders were defined as those with a mean increase of one or more complete spontaneous bowel movements per week compared with the baseline period. Stool form assessed using the 8-point Bristol Stool Form chart (0=separate hard lumps, 7=watery, unformed stools). <BR/>Straining: 3-point scale (0=none, 2=too much).<BR/>Bothersomeness: 5-point scale (0=none, 4 a very great deal).<BR/>Satisfaction: 5-point scale (0=a very great deal to 4=not at all).</P>
<P>A priori sample size calculation of 395 patients in each group to detect a treatment difference in outcomes at the 5% significance level, with 90% power (assuming a responder rate of 30% in the placebo group and 42% in one of the tegaserod groups).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kamm-2005">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 128-centre study.<BR/>Duration 14 weeks (2 weeks treatment-free baseline, 12 weeks DB treatment).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years (86% F). <BR/>Mean age 46 years.<BR/>Constipation for 6 months or more, mean 15 years (defined as an average of less than three complete spontaneous bowel movements per week, together with at least one of the following symptoms occurring at least 25% of the time: straining, incomplete evacuation, very hard and/or hard stools).</P>
<P>Exclusion criteria: Constipation caused by a known disease of the colon or pelvic floor dysfunction; metabolic disorders, neurological disorders, or other significant disease that may have prevented patients from completing the study, use of medications that affect GI function, history of laxative abuse, medical history of previously diagnosed C-IBS.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=417)<BR/>Tegaserod 12mg (n=431)<BR/>Placebo (n=416)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete spontaneous bowel movements (responder rate).<BR/>Weekly number of bowel movements (including complete spontaneous, and spontaneous).<BR/>Time to first complete spontaneous bowel movement. <BR/>Stool form.<BR/>Change in other symptoms (sensation of complete evacuation, straining, bothersomeness), satisfaction, laxative use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Responders were defined as those with a mean increase of one or more complete spontaneous bowel movements per week compared with the baseline period. Stool form assessed using the Bristol Stool Form chart (0=separate hard lumps, 7=watery, unformed stools). <BR/>Straining: 0=none, 2=too much.<BR/>Bothersomeness: 0=none, 4 a very great deal.<BR/>Satisfaction: 0=a very great deal to 4=not at all.</P>
<P>A priori sample size calculation of 395 patients in each group to detect a treatment difference in outcomes at the 5% significance level, with 90% power (assuming a responder rate of 30% in the placebo group and 42% in one of the tegaserod groups).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kellow-2003">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 57-centre study.<BR/>Duration: 18 weeks (2 treatment-free baseline, 12 DB treatment, 4 withdrawal)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years (88.1% F). Mean age (SD) in years; 35.9 (12.4) T12mg, 36.0 (12.4) Plac.<BR/>IBS (Rome II criteria). Duration of IBS (mean, SD, in months); 86.3 (77.0) T12mg, 96.5 (96.8) Plac.</P>
<P>Exclusion criteria: D-IBS; history of organic disease of GI tract; drugs affecting GI motility and/or perception; disease affecting bowel motility or likely to compromise a patient's ability to complete the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 12mg (n=259)<BR/>Placebo (n=261)</P>
<P>Other permitted treatments: rescue laxatives or antidiarrhoeals<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Satisfactory relief from IBS symptoms during first four weeks of DB treatment (responder rate).<BR/>Satisfactory relief during weeks 1-12 of DB treatment.<BR/>GI symptoms: abdominal pain/discomfort, bloating, stool frequency, stool consistency, urgency, straining, sensation of complete evacuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Individual symptoms assessed according to mean change from baseline in the number of days with that symptom, normalised to a 28 day interval (last 28 days of treatment).<BR/>A priori sample size calculation of 173 patients per group to detect a 12.5% difference in SGA of Relief responder rates with 80% power, assuming a 32.5% placebo response.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Khoshoo-2006">
<CHAR_METHODS>
<P>Randomised open controlled parallel group study.<BR/>Duration: 4 weeks treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F 13-18 years (60% F).<BR/>Mean age (SD) 15 years. C-IBS (Rome II criteria).<BR/>Duration of IBS (mean in months, SD) 7.38 (2.27) T12mg + laxative, 6.93 (2.27) laxative.</P>
<P>Exclusion criteria: underlying illness or taking any concomitant drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 12mg + polyethylene glycol 17g (n=21)<BR/>Polyethylene glycol 17g (n=27)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abdominal pain.<BR/>Bowel movements.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abdominal pain measured on a scale of 0-10, none-worse possible.<BR/>a priori sample size calculation of 21 patients in each group to detect a 50% difference in outcomes at the 5% significance level, with 90% power.<BR/>Prior to initiation of study medication, all patients underwent a bowel 'cleanout'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lefkowitz-1999a">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group dose-ranging 45-centre study.<BR/>Duration 16 weeks (4 baseline, 12 DB treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years.<BR/>C-IBS (Rome I criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 1mg (n=?)<BR/>Tegaserod 4mg (n=?)<BR/>Tegaserod 12mg (n=?)<BR/>Tegaserod 24mg (n=?)<BR/>Placebo (n=?)</P>
<P>Total n=547</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of GI symptoms.<BR/>Abdominal <BR/>discomfort.<BR/>Quality of life (SF-36).<BR/>SGA of constipation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Responder rates determined for each SGA.<BR/>Abstract publication of study only.<BR/>No details of statistical or other analyses used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lefkowitz-1999b">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 49-centre study.<BR/>Duration: 16 weeks (4 baseline, 12 DB treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;=12 years (87% F).<BR/>Mean age (SD) 43 (13) years. C-IBS (Rome I criteria).<BR/>Minimum of 3 months symptoms.<BR/>Duration of IBS (mean in months, SD) 175 (158).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=265)<BR/>Tegaserod 12mg (267)<BR/>Placebo (n=267)</P>
<P>Other permitted treatments: laxatives for severe constipation; chronic stable doses of bulking agents or antidepressants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of Relief.<BR/>Abdominal pain and discomfort.<BR/>Bowel habit.<BR/>Number of bowel movements.<BR/>Bloating.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abdominal pain, and bloating assessed on a 6-point ordinal scale.<BR/>Stool consistency assessed on a 7-point scale. <BR/>Abstract publication of study only.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Muller_x002d_Lissner-2001">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group 92-centre study. Duration: 16 weeks (4 treatment-free baseline, 12 DB treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F &gt;= 18 years (83% F). Mean age (SD) in years; 45.6 (13.6) T12mg, 45.7 (14.4) T4mg, 46.1 (13.6) Plac.<BR/>C-IBS (Rome I criteria, 88.5% met Rome II criteria).<BR/>Minimum of 3 months symptoms. Duration of IBS (median, in years); 10.0 T12mg &amp; T4mg, 8.2 Plac.<BR/>Organic disease excluded.</P>
<P>Exclusion criteria: history of diarrhoea; drugs affecting GI motility and/or perception; conditions affecting gastric or bowel transit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 4mg (n=299)<BR/>Tegaserod 12mg (n=294)<BR/>Placebo (n=288)</P>
<P>Other permitted treatments: laxatives for severe constipation; loperamide for diarrhoea; chronic stable doses of bulking agents or antidepressants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of Relief (responder rate).<BR/>Abdominal pain and discomfort.<BR/>Bowel habit.<BR/>Bloating.<BR/>Bowel movements.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abdominal pain and discomfort assessed using 100mm VAS.<BR/>Stool consistency assessed using 7-point ordinal scale.<BR/>A priori sample size calculation of 231 patients per group to detect a 15% difference in SGA of Relief responder rates with 80% power, assuming a 30% placebo response.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Novick-2002">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group<BR/>131-centre study.<BR/>Duration: 20 weeks (4 treatment-free baseline, 12 DB treatment, 4 withdrawal).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>F &gt;= 18 years. Mean age (SD) in years; 41.5 (10.8) T12mg, 41.0 (11.7) Plac.<BR/>C-IBS (Rome I criteria).<BR/>Minimum of 3 months symptoms. Duration of IBS (mean, SD, in years); 16.0 (12.2) T12mg, 16.3 (12.9) Plac.<BR/>Organic disease excluded.</P>
<P>Exclusion criteria: Significant diarrhoea; drugs affecting GI motility and/or perception; GI anatomy or conditions that affect bowel transit; cathartic colon.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 12mg (n=767)<BR/>Placebo (n=752)</P>
<P>Other permitted treatments: chronic stable treatment with fibre or bulking agents.<BR/>Prohibited; non-bulking laxatives</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SGA of Relief (responder rate).<BR/>Abdominal pain and discomfort.<BR/>Bowel habit.<BR/>Satisfaction with bowel habit.<BR/>GI symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mean score difference of abdominal pain and discomfort, and of bowel habit reported.<BR/>Stool consistency, and bloating assessed using a 7-point ordinal scale.<BR/>Responder for Satisfaction with bowel habit if very or somewhat satisfied at 50% of assessments.<BR/>More patients in the T group used laxatives than the Plac group, p&lt;0.05.<BR/>A priori sample size calculation of 764 patients per group to detect a 8% difference in SGA of Relief responder rates with 90% power, assuming a 33% placebo response.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nyhlin-2004">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group<BR/>91-centre study.<BR/>Duration: 18 weeks (2 treatment-free baseline, 12 DB treatment, 4 withdrawal).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>M/F 18-65 years (86% F). Mean age (SD) in years; 44.6 (12) T12mg, 44.0 (12.1) Plac.<BR/>C-IBS (Rome II criteria).<BR/>Duration of IBS (mean, in years); 17.4 T12mg, 16.6 Plac.</P>
<P>Exclusion criteria: D-IBS, drugs affecting GI motility and/or perception; mean abdominal pain/discomfort score of 1 or less on a 5-point scale where 1=mild, severe laxative dependence.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tegaserod 12mg (n=327)<BR/>Placebo (n=320)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Satisfactory relief from IBS symptoms during first four weeks of DB treatment (responder rate).<BR/>Satisfactory relief during weeks 1-12 of DB treatment.<BR/>GI symptoms: abdominal pain/discomfort, bloating, stool frequency, stool consistency, urgency, straining, sensation of complete evacuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Individual symptoms assessed according to mean change from baseline in the number of days with that symptom, normalised to a 28 day interval (last 28 days of treatment).<BR/>A priori sample size calculation of 255 patients per group to detect a 12% difference in SGA of Relief responder rates with 90% power, assuming a 33% placebo response.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reilly-2005">
<CHAR_METHODS>
<P>See Tack 2005.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63% of women from the Tack 2005 study who were employed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>First treatment period: Tegaserod 12mg (n=1363)<BR/>Placebo (n=312)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Work Productivity and Activity Impairment (WPAI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The validated WPAI:IBS was modified to make it appropriate to patients with constipation (diarrhoea was eliminated from the description of IBS symptoms in the introduction). The questionnaire was self-administered. Only data for this outcome for the first treatment period were reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tack-2005">
<CHAR_METHODS>
<P>Randomised double-blind placebo-controlled parallel group<BR/>267-centre study.<BR/>Duration: up to 22 weeks (2-week treatment-free baseline, 4-weeks DB treatment, 2-12 week treatment-free interval, 4 weeks repeated treatment).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>F &gt;= 18 years.<BR/>Mean age in years; 41.9 T12mg, 42.6 Plac.</P>
<P>C-IBS (Rome II criteria).<BR/>Duration of IBS (mean, in years); 13.1 T12mg, 13.4 Plac.</P>
<P>Exclusion criteria: Diarrhoea at least 25% of the time during the previous 3 months, history of cathartic colon or laxative abuse, or any other significant bowel disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>First treatment period: Tegaserod 12mg (n=2135)<BR/>Placebo (n=525).<BR/>Second treatment period: Tegaserod 12mg (n=488)<BR/>Placebo (n=495).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Satisfactory relief from IBS symptoms; abdominal discomfort/pain.<BR/>Relief of constipation.<BR/>Improvement in abdominal discomfort/pain, bloating, mean stool consistency.<BR/>Overall satisfaction with treatment.<BR/>Quality of life.<BR/>Work Productivity and Activity Impairment (WPAI:IBS - reported in Reilly 2005)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients with at least partial response (satisfactory relief of either overall IBS symptoms for at least 2 of 4 weeks treatment or abdominal pain/discomfort in at least 2 of the 4 weeks) entered the treatment free interval. Patients were eligible for repeated treatment if symptoms recurred within 12 weeks (absence of satisfactory relief of overall IBS symptoms for at least 3 of 4 consecutive weeks and abdominal pain/discomfort for at least 3 of 4 consecutive weeks).<BR/>Data available for the first tegaserod treatment period only.<BR/>The validated WPAI:IBS was modified to make it appropriate to patients with constipation (diarrhoea was eliminated from the description of IBS symptoms in the introduction). The questionnaire was self-administered.<BR/>A priori sample size calculation for the first treatment period of 2000 tegaserod and 500 placebo to detect a 15% difference in responder rates for overall relief of GI symptoms, and 10% for relief of abdominal discomfort/pain during first and repeated treatment simultaneously with 90% power at a two-sided significance level of 5%.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Appel_x002d_Dingemanse">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical endpoints, purely a pharmacokinetic study.<BR/>Comparator arm not appropriate (healthy volunteers).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bardhan-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>In this study all patients received tegaserod, with responders then randomised to continue or to withdraw tegaserod treatment. There was no control group. The study was also open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prather-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical endpoints.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tougas-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.<BR/>All patients received tegaserod treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Anon-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Chey-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lin-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Munoz-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-B307">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamling-1998">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Johanson-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kamm-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kellow-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Khoshoo-2006">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lefkowitz-1999a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lefkowitz-1999b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muller_x002d_Lissner-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Novick-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nyhlin-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Reilly-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tack-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-12 12:32:52 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-06-12 12:32:30 -0400" MODIFIED_BY="John K MacDonald" NO="1">
<TITLE>SGA of Relief responder rates</TITLE>
<TABLE COLS="5" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>B307</P>
</TD>
<TD>
<P>42.2%</P>
</TD>
<TD>
<P>38.3%</P>
</TD>
<TD>
<P>37.0%</P>
</TD>
<TD>
<P>Applies to last 4 weeks of DB treatment. In the 12 mg group, patients started on 4 mg for one month, which could be increased to 12 mg according to response (65% of patients took 12 mg after the first month). The responder rate is adjusted for missing SGAs, laxative use, and duration of treatment. P = 0.142 for 12 mg vs placebo, P = 0.837 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Kellow 2003</P>
</TD>
<TD>
<P>46.8%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>28.3%</P>
</TD>
<TD>
<P>Applies to weeks 1 to 4 of DB treatment. P &lt; 0.0001 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Lefkowitz 1999b</P>
</TD>
<TD>
<P>45.7%</P>
</TD>
<TD>
<P>38.9%</P>
</TD>
<TD>
<P>33.3%</P>
</TD>
<TD>
<P>Applies to last 4 weeks of DB treatment. The responder rate is adjusted for missing SGAs, laxative use, and duration of treatment. P = 0.004 for 12 mg vs placebo, P = 0.157 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>38.4%</P>
</TD>
<TD>
<P>38.8%</P>
</TD>
<TD>
<P>30.2%</P>
</TD>
<TD>
<P>Applies to last 4 weeks of DB treatment. The responder rate is adjusted for missing SGAs, laxative use, and duration of treatment. P = 0.033 for 12 mg vs placebo, P = 0.018 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>43.5%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>38.8%</P>
</TD>
<TD>
<P>Applies to last 4 weeks of DB treatment. The responder rate is adjusted for missing SGAs, laxative use, and duration of treatment. P &lt; 0.033 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Hamling 1998</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>Responder rates reported in abstract but not for ITT population, or for each tegaserod dosage group</P>
</TD>
</TR>
<TR>
<TD>
<P>Lefkowitz 1999a</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>30.5%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>20.8%</P>
</TD>
<TD>
<P>Applies to weeks 1 to 4 of DB treatment. P = 0.006 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>31%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>20.4%</P>
</TD>
<TD>
<P>Applies to weeks 1 to 12 of DB treatment. P = 0.0027 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Tack 2005</P>
</TD>
<TD>
<P>33.7%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>24.2%</P>
</TD>
<TD>
<P>Applies to weeks 1 to 4 of DB treatment. Difference in response rate 9.3%, 95% CI 5.3 to 13.3), P &lt; 0.0001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-06-12 12:32:43 -0400" MODIFIED_BY="John K MacDonald" NO="2">
<TITLE>Abdominal pain and discomfort responder rates</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>B307</P>
</TD>
<TD>
<P>27.6%</P>
</TD>
<TD>
<P>25.5%</P>
</TD>
<TD>
<P>30.6%</P>
</TD>
<TD>
<P>In the 12 mg group, patients started on 4 mg for one month, which could be increased to 12 mg according to response (65% of patients took 12 mg after the first month). P = 0.411 for 12 mg vs placebo, P = 0.141 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Hamling 1998</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>Responder rates reported in abstract but not for ITT population, or for each tegaserod dosage group</P>
</TD>
</TR>
<TR>
<TD>
<P>Lefkowitz 1999a</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P>No numerical data</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lefkowitz 1999b</P>
</TD>
<TD>
<P>25.1%</P>
</TD>
<TD>
<P>23.4%</P>
</TD>
<TD>
<P>18.7%</P>
</TD>
<TD>
<P>P = 0.075 for 12 mg vs placebo, P = 0.185 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>29.9%</P>
</TD>
<TD>
<P>29.8%</P>
</TD>
<TD>
<P>22.6%</P>
</TD>
<TD>
<P>P = 0.044 for 12 mg vs placebo, P = 0.055 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>No responder rate</P>
</TD>
<TD>
<P>No 4mg group</P>
</TD>
<TD>
<P>No responder rate</P>
</TD>
<TD>
<P>Mean score differences reported on 7-point scale (endpoint minus baseline); -1.01 for 12 mg, -0.80 for placebo, P &lt; 0.003</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-06-12 12:32:50 -0400" MODIFIED_BY="John K MacDonald" NO="3">
<TITLE>Bowel habit responder rates</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>B307</P>
</TD>
<TD>
<P>24.0%</P>
</TD>
<TD>
<P>27.0%</P>
</TD>
<TD>
<P>25.0%</P>
</TD>
<TD>
<P>In the 12 mg group, patients started on 4 mg for one month, which could be increased to 12 mg according to response (65% took 12mg after the first month). P = 0.847 for 12 mg vs placebo, P = 0.661 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Lefkowitz 1999b</P>
</TD>
<TD>
<P>24.7%</P>
</TD>
<TD>
<P>26.4%</P>
</TD>
<TD>
<P>20.2%</P>
</TD>
<TD>
<P>P = 0.218 for 12 mg vs placebo, P = 0.082 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>26.2%</P>
</TD>
<TD>
<P>28.8%</P>
</TD>
<TD>
<P>22.6%</P>
</TD>
<TD>
<P>P = 0.337 for 12 mg vs placebo, P = 0.096 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>No responder rate</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>No responder rate</P>
</TD>
<TD>
<P>Mean score difference (endpoint minus baseline) reported, on a 7-point ordinal scale; -1.30 for 12 mg, -0.95 for placebo, P &lt; 0.001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Satisfaction with bowel habit response rates</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TH>
<P>Novick 2002</P>
</TH>
<TH>
<P>Month 1</P>
</TH>
<TH>
<P>Month 2</P>
</TH>
<TH>
<P>Month 3</P>
</TH>
</TR>
<TR>
<TD>
<P>Tegaserod 12 mg</P>
</TD>
<TD>
<P>56.0%</P>
</TD>
<TD>
<P>58.7%</P>
</TD>
<TD>
<P>60.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>41.1%</P>
</TD>
<TD>
<P>50.1%</P>
</TD>
<TD>
<P>52.7%</P>
</TD>
</TR>
<TR>
<TD>
<P>P for tegaserod vs placebo</P>
</TD>
<TD>
<P>P &lt; 0.001</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>P = 0.007</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Diarrhoea (adverse effect)</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Fidelholtz 2002</P>
</TD>
<TD>
<P>17.6%</P>
</TD>
<TD>
<P>48.6%</P>
</TD>
<TD>
<P>35.3%</P>
</TD>
<TD>
<P>Study included D-IBS patients. P = NS between groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Kellow 2003</P>
</TD>
<TD>
<P>10.0%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>3.1%</P>
</TD>
<TD>
<P>Study included C-IBS patients. P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>9.6%</P>
</TD>
<TD>
<P>7.1%</P>
</TD>
<TD>
<P>2.5%</P>
</TD>
<TD>
<P>Study included C-IBS patients. P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>6.4%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>2.9%</P>
</TD>
<TD>
<P>Study included C-IBS patients. P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>9.2%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
<TD>
<P>Study included C-IBS patients. P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>5.8%</P>
</TD>
<TD>
<P>3.9%</P>
</TD>
<TD>
<P>2.2%</P>
</TD>
<TD>
<P>Study included patients with chronic constipation. P = 0.1516 for 4 mg vs placebo, P = 0.0072 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>7.3%</P>
</TD>
<TD>
<P>4.5%</P>
</TD>
<TD>
<P>3.8%</P>
</TD>
<TD>
<P>Study included C-IBS patients. P value not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Headache (adverse effect)</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Fidelholtz 2002</P>
</TD>
<TD>
<P>20.6%</P>
</TD>
<TD>
<P>28.6%</P>
</TD>
<TD>
<P>23.5%</P>
</TD>
<TD>
<P>P = NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Kellow 2003</P>
</TD>
<TD>
<P>12.0%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>11.1%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>27.3%</P>
</TD>
<TD>
<P>30.6%</P>
</TD>
<TD>
<P>27.3%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>9.0%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>5.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>8.0%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>12.3%</P>
</TD>
<TD>
<P>11.1%</P>
</TD>
<TD>
<P>13.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>9.8%</P>
</TD>
<TD>
<P>9.2%</P>
</TD>
<TD>
<P>12.8%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Abdominal pain (adverse effect)</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Fidelholtz 2002</P>
</TD>
<TD>
<P>20.6%</P>
</TD>
<TD>
<P>31.4%</P>
</TD>
<TD>
<P>23.5%</P>
</TD>
<TD>
<P>P = NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Kellow 2003</P>
</TD>
<TD>
<P>5.8%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>3.1%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>16.7%</P>
</TD>
<TD>
<P>16.5%</P>
</TD>
<TD>
<P>17.1%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>6.4%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>5.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>4.9%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>3.8%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Nausea (adverse effect)</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Kellow 2003</P>
</TD>
<TD>
<P>4.2%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>3.4%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-Lissner 2001</P>
</TD>
<TD>
<P>7.2%</P>
</TD>
<TD>
<P>7.4%</P>
</TD>
<TD>
<P>8.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Novick 2002</P>
</TD>
<TD>
<P>6.8%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Nyhlin 2004</P>
</TD>
<TD>
<P>5.5%</P>
</TD>
<TD>
<P>No 4 mg group</P>
</TD>
<TD>
<P>5.1%</P>
</TD>
<TD>
<P>P value not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" NO="9">
<TITLE>Abdominal pain</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Teg 12 mg + laxative</P>
</TH>
<TH>
<P>Laxative</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Khoshoo 2006</P>
</TD>
<TD>
<P>Mean pain score at 4 weeks</P>
</TD>
<TD>
<P>4.29 (SD 2.31)</P>
</TD>
<TD>
<P>6.15 (SD 2.38)</P>
</TD>
<TD>
<P>Scored on a scale of 0 to 10. P &lt; 0.05 between groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Khosoo 2006</P>
</TD>
<TD>
<P>% with good pain reduction (3 or more points on scale)</P>
</TD>
<TD>
<P>66.7%</P>
</TD>
<TD>
<P>18.5%</P>
</TD>
<TD>
<P>P &lt; 0.05 between groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Khosoo 2006</P>
</TD>
<TD>
<P>% with no pain reduction (2 points or less on pain scale)</P>
</TD>
<TD>
<P>23.8%</P>
</TD>
<TD>
<P>59.3%</P>
</TD>
<TD>
<P>P &lt; 0.05 between groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Khosoo 2006</P>
</TD>
<TD>
<P>% with increased pain (not defined)</P>
</TD>
<TD>
<P>9.5%</P>
</TD>
<TD>
<P>22.2%</P>
</TD>
<TD>
<P>P &lt; 0.05 between groups</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" NO="10">
<TITLE>Responder rate for complete spontaneous bowel movements</TITLE>
<TABLE COLS="6" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Week assessed</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>35.6%</P>
</TD>
<TD>
<P>40.2%</P>
</TD>
<TD>
<P>26.7%</P>
</TD>
<TD>
<P>P &lt; 0.0001 for 12 mg vs placebo, P = 0.059 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>no numerical data</P>
</TD>
<TD>
<P>43.2%</P>
</TD>
<TD>
<P>30.6%</P>
</TD>
<TD>
<P>P &lt; 0.0001 for 12 mg vs placebo, P = 0.14 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>41.4%</P>
</TD>
<TD>
<P>43.2%</P>
</TD>
<TD>
<P>25.1%</P>
</TD>
<TD>
<P>P &lt; 0.0001 for 12 mg vs placebo, P &lt; 0.0001 for 4 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>40.3%</P>
</TD>
<TD>
<P>44.8%</P>
</TD>
<TD>
<P>26.9%</P>
</TD>
<TD>
<P>P &lt; 0.0001 for 12 mg vs placebo, P &lt; 0.0001 for 4 mg vs placebo</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" NO="11">
<TITLE>Time to first bowel movement (median)</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tegaserod 4 mg</P>
</TH>
<TH>
<P>Tegaserod 12 mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>174.3</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>286.3</P>
</TD>
<TD>
<P>Hours to CSBM. P &lt; 0.007 for 4 mg and 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>117</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>229</P>
</TD>
<TD>
<P>Hours to CSBM. P &lt; 0.01 for 4 mg and P &lt; 0.001 for 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamm 2005</P>
</TD>
<TD>
<P>21.3</P>
</TD>
<TD>
<P>18.4</P>
</TD>
<TD>
<P>37.2</P>
</TD>
<TD>
<P>Hours to SBM. P &lt; 0.001 for 4 mg and 12 mg vs placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Johanson 2004</P>
</TD>
<TD>
<P>data shown in graph only</P>
</TD>
<TD>
<P>data shown in graph only</P>
</TD>
<TD>
<P>data shown in graph only</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" MODIFIED="2008-06-12 12:32:52 -0400" MODIFIED_BY="John K MacDonald" NO="12">
<TITLE>Outcomes of repeated tegaserod treatment (Tack 2005)</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Tegaserod 12mg</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Satisfactory relief of overall IBS symptoms (75% of the time)</P>
</TD>
<TD>
<P>44.9%</P>
</TD>
<TD>
<P>28.7%</P>
</TD>
<TD>
<P>(difference in response rate 16.6%, 95% CI 10.5 to 22.2), P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Satisfactory relief of abdominal pain and discomfort (75% of the time)</P>
</TD>
<TD>
<P>42.4%</P>
</TD>
<TD>
<P>27.1%</P>
</TD>
<TD>
<P>(difference in response rate 15.9%, 95% CI 10.3 to 21.5), P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Satisfactory relief of constipation (75% of the time)</P>
</TD>
<TD>
<P>45.1%</P>
</TD>
<TD>
<P>27.5%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Improvement in abdominal pain and discomfort</P>
</TD>
<TD>
<P>54.2%</P>
</TD>
<TD>
<P>41.8%</P>
</TD>
<TD>
<P>P &lt; 0.0001 (1-point or greater improvement on 7-point scale)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Tegaserod 12mg vs placebo</NAME>
<DICH_OUTCOME CHI2="3.087144048438992" CI_END="1.293859845348603" CI_START="1.0882408852624976" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1866048978104557" ESTIMABLE="YES" EVENTS_1="685" EVENTS_2="573" I2="2.822804737053201" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.11188723484248363" LOG_CI_START="0.03672503834101076" LOG_EFFECT_SIZE="0.07430613659174722" METHOD="MH" NO="1" P_CHI2="0.3783837184227006" P_Q="0.0" P_Z="1.0650131325911154E-4" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1603" TOTAL_2="1591" WEIGHT="99.99999999999999" Z="3.875281945686204">
<NAME>SGA of Relief at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4011233610865084" CI_START="0.9290354767806731" EFFECT_SIZE="1.1409177489177489" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="105" LOG_CI_END="0.1464763741727064" LOG_CI_START="-0.03196770142519556" LOG_EFFECT_SIZE="0.05725433637375542" ORDER="10797" O_E="0.0" SE="0.10481893331862771" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="284" VAR="0.010987008782054922" WEIGHT="17.964058769063193"/>
<DICH_DATA CI_END="1.6981999432263286" CI_START="1.1064984911132485" EFFECT_SIZE="1.3707865168539326" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="89" LOG_CI_END="0.22998882202561852" LOG_CI_START="0.04395082603405235" LOG_EFFECT_SIZE="0.13696982402983543" ORDER="10798" O_E="0.0" SE="0.10927963974837827" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="267" VAR="0.011942039663535338" WEIGHT="15.475842213327498"/>
<DICH_DATA CI_END="1.5973346557487909" CI_START="1.0134743980626624" EFFECT_SIZE="1.2723434201266715" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="87" LOG_CI_END="0.20339591420927508" LOG_CI_START="0.00581278221447457" LOG_EFFECT_SIZE="0.10460434821187478" ORDER="10799" O_E="0.0" SE="0.11606130978602301" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.013470227629247203" WEIGHT="15.284029967662486"/>
<DICH_DATA CI_END="1.2651869837252692" CI_START="0.9940711475293881" EFFECT_SIZE="1.121465949884803" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="292" LOG_CI_END="0.10215471523438314" LOG_CI_START="-0.0025825312227681107" LOG_EFFECT_SIZE="0.04978609200580749" ORDER="10800" O_E="0.0" SE="0.06152317702666218" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.0037851013114540127" WEIGHT="51.27606904994681"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.241446168000447" CI_END="1.5135862442701384" CI_START="0.8875378005198036" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1590362402170817" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="202" I2="61.84259198901632" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.18000717213335185" LOG_CI_START="-0.05181314113758313" LOG_EFFECT_SIZE="0.06409701549788437" METHOD="MH" NO="2" P_CHI2="0.07275036470063656" P_Q="0.0" P_Z="0.27843661347468185" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03433612068443031" TOTALS="YES" TOTAL_1="836" TOTAL_2="839" WEIGHT="100.0" Z="1.0838380823472897">
<NAME>Abdominal pain and discomfort at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1691390742804775" CI_START="0.696135523625595" EFFECT_SIZE="0.9021525600835946" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="87" LOG_CI_END="0.06786617549038383" LOG_CI_START="-0.15730620373248813" LOG_EFFECT_SIZE="-0.04472001412105214" ORDER="10801" O_E="0.0" SE="0.13226737017676848" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="284" VAR="0.017494657213478308" WEIGHT="35.77589059960701"/>
<DICH_DATA CI_END="1.8539286200125666" CI_START="0.9685378285965665" EFFECT_SIZE="1.34" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="50" LOG_CI_END="0.26809300891773774" LOG_CI_START="-0.013883412188122423" LOG_EFFECT_SIZE="0.12710479836480765" ORDER="10802" O_E="0.0" SE="0.16563434556337797" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="267" VAR="0.02743473643020851" WEIGHT="30.0188847359974"/>
<DICH_DATA CI_END="1.748295255927964" CI_START="1.006037493713718" EFFECT_SIZE="1.3262166405023548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="65" LOG_CI_END="0.24261477909468865" LOG_CI_START="0.002614166614084558" LOG_EFFECT_SIZE="0.1226144728543866" ORDER="10803" O_E="0.0" SE="0.14097754779329877" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.01987466898181184" WEIGHT="34.20522466439559"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9258693160466308" CI_END="1.2862214079503806" CI_START="1.0391632028146336" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1561115680653251" ESTIMABLE="YES" EVENTS_1="447" EVENTS_2="379" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.10931573373170148" LOG_CI_START="0.016683759795635068" LOG_EFFECT_SIZE="0.06299974676366826" METHOD="MH" NO="3" P_CHI2="0.3359387330188298" P_Q="0.0" P_Z="0.007676554260324256" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1061" TOTAL_2="1040" WEIGHT="100.00000000000003" Z="2.665974381095586">
<NAME>SGA of relief at endpoint (fully published studies only)</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5973346557487909" CI_START="1.0134743980626624" EFFECT_SIZE="1.2723434201266715" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="87" LOG_CI_END="0.20339591420927508" LOG_CI_START="0.00581278221447457" LOG_EFFECT_SIZE="0.10460434821187478" ORDER="10804" O_E="0.0" SE="0.11606130978602301" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.013470227629247203" WEIGHT="22.962751247739142"/>
<DICH_DATA CI_END="1.2651869837252692" CI_START="0.9940711475293881" EFFECT_SIZE="1.121465949884803" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="292" LOG_CI_END="0.10215471523438314" LOG_CI_START="-0.0025825312227681107" LOG_EFFECT_SIZE="0.04978609200580749" ORDER="10805" O_E="0.0" SE="0.06152317702666218" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.0037851013114540127" WEIGHT="77.03724875226088"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3957143304993527" CI_END="1.3109750986306148" CI_START="0.9299773729796357" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1041635649966983" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="190" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.11759444254437591" LOG_CI_START="-0.03152761801556124" LOG_EFFECT_SIZE="0.04303341226440735" METHOD="MH" NO="4" P_CHI2="0.49765060279146534" P_Q="0.0" P_Z="0.2579681147397326" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="836" TOTAL_2="839" WEIGHT="100.0" Z="1.1312067155375984">
<NAME>Bowel habit</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.284546894026636" CI_START="0.7174514253123794" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="71" LOG_CI_END="0.10874996336706536" LOG_CI_START="-0.14420749728792853" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="10806" O_E="0.0" SE="0.14858846454836816" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="284" VAR="0.02207853179684166" WEIGHT="36.85854302568465"/>
<DICH_DATA CI_END="1.6783208824287792" CI_START="0.8900724385506292" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="54" LOG_CI_END="0.224874998295575" LOG_CI_START="-0.05057464685777464" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="10807" O_E="0.0" SE="0.1618004850608113" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="267" VAR="0.026179396965913822" WEIGHT="28.491984117114384"/>
<DICH_DATA CI_END="1.546776265174194" CI_START="0.8705977740623706" EFFECT_SIZE="1.1604395604395605" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="65" LOG_CI_END="0.18942749933136022" LOG_CI_START="-0.06018244757796042" LOG_EFFECT_SIZE="0.0646225258766999" ORDER="10808" O_E="0.0" SE="0.14662211840369946" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.021498045605188462" WEIGHT="34.64947285720096"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.757062226820279" CI_END="3.6807696765188886" CI_START="2.1325906825888516" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.801709320557678" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="67" I2="26.003345356893554" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5659386424000876" LOG_CI_START="0.3289075074178045" LOG_EFFECT_SIZE="0.44742307490894606" METHOD="MH" NO="5" P_CHI2="0.2393441327175947" P_Q="0.0" P_Z="1.3689664256598643E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2529" TOTAL_2="2481" WEIGHT="100.00000000000001" Z="7.399307375710348">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4031623924248224" CI_START="1.08770049509154" EFFECT_SIZE="1.9239598278335726" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5318826732954245" LOG_CI_START="0.036509326211754456" LOG_EFFECT_SIZE="0.2841959997535895" ORDER="10813" O_E="0.0" SE="0.2909847562145634" STUDY_ID="STD-Johanson-2004" TOTAL_1="451" TOTAL_2="447" VAR="0.08467212834924889" WEIGHT="25.276448872530374"/>
<DICH_DATA CI_END="5.675290216593089" CI_START="1.2665987191275154" EFFECT_SIZE="2.6811033771590616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7539880748946314" LOG_CI_START="0.10263904450281638" LOG_EFFECT_SIZE="0.42831355969872387" ORDER="10814" O_E="0.0" SE="0.38260564468185226" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" VAR="0.1463870793424158" WEIGHT="13.55823951936452"/>
<DICH_DATA CI_END="7.09860309852199" CI_START="1.5110377492344464" EFFECT_SIZE="3.275096525096525" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.8511728943118481" LOG_CI_START="0.17927531415995904" LOG_EFFECT_SIZE="0.5152241042359035" ORDER="10809" O_E="0.0" SE="0.39467596452788145" STUDY_ID="STD-Kellow-2003" TOTAL_1="259" TOTAL_2="261" VAR="0.15576911697601353" WEIGHT="11.796504563355157"/>
<DICH_DATA CI_END="8.826992446501434" CI_START="1.7393922968226163" EFFECT_SIZE="3.9183673469387754" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="0.9458127549498455" LOG_CI_START="0.24039754240022623" LOG_EFFECT_SIZE="0.5931051486750359" ORDER="10810" O_E="0.0" SE="0.41436438771326456" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.17169784580498865" WEIGHT="10.468617173108436"/>
<DICH_DATA CI_END="3.5746535201572875" CI_START="1.3340060472567574" EFFECT_SIZE="2.1837145904942514" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="22" LOG_CI_END="0.553233953388556" LOG_CI_START="0.1251577983093815" LOG_EFFECT_SIZE="0.3391958758489687" ORDER="10811" O_E="0.0" SE="0.2514540525046497" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.06322914052101111" WEIGHT="32.88722302605496"/>
<DICH_DATA CI_END="20.401609130428113" CI_START="2.5910817960069807" EFFECT_SIZE="7.270642201834862" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="4" LOG_CI_END="1.3096644227643939" LOG_CI_START="0.41348112313393703" LOG_EFFECT_SIZE="0.8615727729491655" ORDER="10812" O_E="0.0" SE="0.5264225063818093" STUDY_ID="STD-Nyhlin-2004" TOTAL_1="327" TOTAL_2="317" VAR="0.27712065522530605" WEIGHT="6.012966845586558"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.604807117543457" CI_END="1.2382783066320722" CI_START="0.916925237856515" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0655555503309884" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="279" I2="52.85157057002446" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.092818264596022" LOG_CI_START="-0.03766607339215716" LOG_EFFECT_SIZE="0.02757609560193243" METHOD="MH" NO="6" P_CHI2="0.059803701916420815" P_Q="0.0" P_Z="0.40743063895679754" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2529" TOTAL_2="2481" WEIGHT="100.00000000000001" Z="0.8284236261200523">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1086673414038282" CI_START="0.5279786359472513" EFFECT_SIZE="0.7650834403080873" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.04480125447640877" LOG_CI_START="-0.2773836503410647" LOG_EFFECT_SIZE="-0.11629119793232802" ORDER="10819" O_E="0.0" SE="0.18925300793078406" STUDY_ID="STD-Johanson-2004" TOTAL_1="451" TOTAL_2="447" VAR="0.03581670101084942" WEIGHT="20.33066736168683"/>
<DICH_DATA CI_END="1.2721546827510917" CI_START="0.6331319468555692" EFFECT_SIZE="0.8974640778279807" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.10453992088862324" LOG_CI_START="-0.19850577210000567" LOG_EFFECT_SIZE="-0.04698292560569119" ORDER="10820" O_E="0.0" SE="0.17801054016189422" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" VAR="0.03168775240872935" WEIGHT="20.59895976757029"/>
<DICH_DATA CI_END="1.7343844304418226" CI_START="0.6690576059140616" EFFECT_SIZE="1.0772200772200773" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.23914536621694588" LOG_CI_START="-0.17453648783225442" LOG_EFFECT_SIZE="0.03230443919234575" ORDER="10815" O_E="0.0" SE="0.24299876882670363" STUDY_ID="STD-Kellow-2003" TOTAL_1="259" TOTAL_2="261" VAR="0.05904840165129375" WEIGHT="10.258195987710586"/>
<DICH_DATA CI_END="1.3111436899469264" CI_START="0.7698937501080123" EFFECT_SIZE="1.0047095761381475" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="78" LOG_CI_END="0.11765028919693095" LOG_CI_START="-0.11356920589985746" LOG_EFFECT_SIZE="0.002040541648536706" ORDER="10816" O_E="0.0" SE="0.1358194759748134" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.018446930054072913" WEIGHT="27.983080531804937"/>
<DICH_DATA CI_END="2.271484303534013" CI_START="1.0896737363180056" EFFECT_SIZE="1.5732694581728874" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="43" LOG_CI_END="0.35630974008874017" LOG_CI_START="0.03729648351191999" LOG_EFFECT_SIZE="0.19680311180033008" ORDER="10817" O_E="0.0" SE="0.1873899660543123" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.03511499937783631" WEIGHT="15.419937716344323"/>
<DICH_DATA CI_END="3.112458897286603" CI_START="0.9071593309493315" EFFECT_SIZE="1.6803261977573904" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.49310362490717075" LOG_CI_START="-0.04231642796196645" LOG_EFFECT_SIZE="0.22539359847260215" ORDER="10818" O_E="0.0" SE="0.3145083894273376" STUDY_ID="STD-Nyhlin-2004" TOTAL_1="327" TOTAL_2="317" VAR="0.09891552702017785" WEIGHT="5.409158634883045"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.350242424270607" CI_END="1.2764302037848787" CI_START="0.8252977580906034" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.026369809348849" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="143" I2="25.237032590250973" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.10599707222306196" LOG_CI_START="-0.08338933464371635" LOG_EFFECT_SIZE="0.01130386878967282" METHOD="MH" NO="7" P_CHI2="0.2532104149854366" P_Q="0.0" P_Z="0.81500985210578" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2078" TOTAL_2="2034" WEIGHT="100.0" Z="0.2339679608506423">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.118980662662564" CI_START="0.38205399145342467" EFFECT_SIZE="0.6538432752039518" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="31" LOG_CI_END="0.048822581459978844" LOG_CI_START="-0.4178752587286633" LOG_EFFECT_SIZE="-0.18452633863434226" ORDER="10825" O_E="0.0" SE="0.27414062151837565" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" VAR="0.0751530803664813" WEIGHT="21.81293649539875"/>
<DICH_DATA CI_END="4.379668558104469" CI_START="0.8151598583435635" EFFECT_SIZE="1.8894787644787645" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6414412454737815" LOG_CI_START="-0.08875721483224787" LOG_EFFECT_SIZE="0.2763420153207668" ORDER="10821" O_E="0.0" SE="0.4289221901244347" STUDY_ID="STD-Kellow-2003" TOTAL_1="259" TOTAL_2="261" VAR="0.18397424518114172" WEIGHT="5.509916136868049"/>
<DICH_DATA CI_END="1.4056162050550713" CI_START="0.682690028150077" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="49" LOG_CI_END="0.14786675540629649" LOG_CI_START="-0.16577644071214942" LOG_EFFECT_SIZE="-0.008954842652926452" ORDER="10822" O_E="0.0" SE="0.18423556595883525" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.033942743764172334" WEIGHT="34.22780169168937"/>
<DICH_DATA CI_END="1.661763370979516" CI_START="0.751157521483973" EFFECT_SIZE="1.117249325369152" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="43" LOG_CI_END="0.22056918190639155" LOG_CI_START="-0.1242689797232147" LOG_EFFECT_SIZE="0.048150101091588446" ORDER="10823" O_E="0.0" SE="0.2025596431176606" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.04103040901995402" WEIGHT="30.023728695603268"/>
<DICH_DATA CI_END="2.6884930362824955" CI_START="0.6214290858106943" EFFECT_SIZE="1.292558613659531" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4295089159077995" LOG_CI_START="-0.20660842357626874" LOG_EFFECT_SIZE="0.11145024616576536" ORDER="10824" O_E="0.0" SE="0.3736584740445559" STUDY_ID="STD-Nyhlin-2004" TOTAL_1="327" TOTAL_2="317" VAR="0.13962065522530603" WEIGHT="8.425616980440566"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.889535868052535" CI_END="1.565568088679513" CI_START="0.932832087997373" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2084751338215307" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.19467196041971901" LOG_CI_START="-0.03019652326204512" LOG_EFFECT_SIZE="0.08223771857883694" METHOD="MH" NO="8" P_CHI2="0.5764782597520759" P_Q="0.0" P_Z="0.15169345922042068" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2078" TOTAL_2="2034" WEIGHT="99.99999999999999" Z="1.4335754299243502">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8194704044777152" CI_START="0.7058055645371207" EFFECT_SIZE="1.4106728538283062" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.4501675402297538" LOG_CI_START="-0.15131492200574712" LOG_EFFECT_SIZE="0.1494263091120033" ORDER="10830" O_E="0.0" SE="0.35331377570333994" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" VAR="0.12483062410174998" WEIGHT="13.357466178810968"/>
<DICH_DATA CI_END="2.922287236219123" CI_START="0.5191094521618705" EFFECT_SIZE="1.2316602316602316" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.465722901185571" LOG_CI_START="-0.2847410632337124" LOG_EFFECT_SIZE="0.0904909189759293" ORDER="10826" O_E="0.0" SE="0.4408262475564234" STUDY_ID="STD-Kellow-2003" TOTAL_1="259" TOTAL_2="261" VAR="0.19432778053467709" WEIGHT="9.051609320693133"/>
<DICH_DATA CI_END="1.4361497138893964" CI_START="0.47146468853675944" EFFECT_SIZE="0.8228571428571428" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.15719971603918895" LOG_CI_START="-0.3265508292212785" LOG_EFFECT_SIZE="-0.08467555659104478" ORDER="10827" O_E="0.0" SE="0.28415746488981725" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="288" VAR="0.08074546485260771" WEIGHT="25.50064853048126"/>
<DICH_DATA CI_END="2.209341734006987" CI_START="0.9604011147738465" EFFECT_SIZE="1.4566585956416465" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="35" LOG_CI_END="0.34426289636707963" LOG_CI_START="-0.01754734451271008" LOG_EFFECT_SIZE="0.16335777592718478" ORDER="10828" O_E="0.0" SE="0.21252912648236555" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.04516862960335733" WEIGHT="35.68555910879856"/>
<DICH_DATA CI_END="2.1005386036672373" CI_START="0.5662358947049464" EFFECT_SIZE="1.0905963302752293" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.32233066740488664" LOG_CI_START="-0.24700260339519325" LOG_EFFECT_SIZE="0.03766403200484668" ORDER="10829" O_E="0.0" SE="0.3344291815131094" STUDY_ID="STD-Nyhlin-2004" TOTAL_1="327" TOTAL_2="317" VAR="0.11184287744752827" WEIGHT="16.404716861216077"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5834770814128294" CI_END="1.7481418568589076" CI_START="1.3505772653727368" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5365547984110823" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="247" I2="36.84783873804048" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.24257667151996956" LOG_CI_START="0.1305194348508674" LOG_EFFECT_SIZE="0.18654805318541848" METHOD="MH" NO="9" P_CHI2="0.20826060508787592" P_Q="0.0" P_Z="6.767249618910373E-11" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="882" TOTAL_2="863" WEIGHT="100.0" Z="6.525726967713066">
<NAME>Complete spontaneous bowel movement responders at week 12</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0057839323980913" CI_START="1.3877718097761307" EFFECT_SIZE="1.6684035476718404" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="120" LOG_CI_END="0.3022841480157995" LOG_CI_START="0.14231806129015032" LOG_EFFECT_SIZE="0.2223011046529749" ORDER="10832" O_E="0.0" SE="0.0939648711875463" STUDY_ID="STD-Johanson-2004" TOTAL_1="451" TOTAL_2="447" VAR="0.00882939701729217" WEIGHT="48.25557159899819"/>
<DICH_DATA CI_END="1.6940398893863915" CI_START="1.1795787360839476" EFFECT_SIZE="1.4135959223194547" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="127" LOG_CI_END="0.22892363240344524" LOG_CI_START="0.07172693505249593" LOG_EFFECT_SIZE="0.15032528372797055" ORDER="10831" O_E="0.0" SE="0.09233811816014911" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" VAR="0.00852632806535766" WEIGHT="51.744428401001805"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.415283552342717" CI_END="0.8282574285097957" CI_START="0.5533941097300783" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.690825769119937" ESTIMABLE="YES" I2="0.0" I2_Q="31.69910517202209" ID="CMP-001.10" NO="10" P_CHI2="0.6362433574733768" P_Q="0.23128387348300827" P_Z="6.711109471862899E-23" Q="2.9282193228027014" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2613" TOTAL_2="2541" UNITS="" WEIGHT="100.0" Z="9.85212310670224">
<NAME>Weekly frequency of bowel movements</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7783200829414406" CI_START="0.4216799170585591" DF="1.0" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="1.0" P_Z="4.259404637835962E-11" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="847" WEIGHT="59.39817009666463" Z="6.5947613489514625">
<NAME>Complete spontaneous bowel movements (CSBM)</NAME>
<CONT_DATA CI_END="0.8534958931661827" CI_START="0.34650410683381705" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.3" ORDER="10833" SD_1="2.1" SD_2="1.7" SE="0.12933701596852087" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="431" WEIGHT="29.392175019080366"/>
<CONT_DATA CI_END="0.8508896660793528" CI_START="0.349110333920647" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.3" ORDER="10834" SD_1="2.1" SD_2="1.6" SE="0.1280072838370187" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" WEIGHT="30.005995077584263"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3757311900079727" CI_END="1.2254048438200271" CI_START="0.5871721501201321" DF="1.0" EFFECT_SIZE="0.9062884969700796" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.5398970330215037" P_Z="2.60226200244016E-8" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="847" WEIGHT="18.547077100570487" Z="5.566285874096978">
<NAME>Spontaneous bowel movements (SBM)</NAME>
<CONT_DATA CI_END="1.266194985367382" CI_START="0.33380501463261936" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="4.6" ORDER="10835" SD_1="3.8" SD_2="3.2" SE="0.23785895508523008" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="431" WEIGHT="8.690372359531413"/>
<CONT_DATA CI_END="1.4377447202250635" CI_START="0.5622552797749366" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.1" ORDER="10836" SD_1="3.3" SD_2="3.2" SE="0.22334324695654506" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" WEIGHT="9.856704741039074"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.11133303953204313" CI_END="1.0468856798522177" CI_START="0.461602977816647" DF="1.0" EFFECT_SIZE="0.7542443288344324" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" NO="3" P_CHI2="0.738631604796676" P_Z="4.3824464592899625E-7" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="847" WEIGHT="22.054752802764877" Z="5.051547619356191">
<NAME>Bowel movements</NAME>
<CONT_DATA CI_END="1.1326266095210809" CI_START="0.2673733904789177" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="5.4" ORDER="10837" SD_1="3.5" SD_2="3.0" SE="0.2207319180013434" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="431" WEIGHT="10.091300168811802"/>
<CONT_DATA CI_END="1.1973365559789184" CI_START="0.4026634440210811" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="4.9" ORDER="10838" SD_1="3.0" SD_2="2.9" SE="0.20272645778854037" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="416" WEIGHT="11.963452633953075"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.2239552456058134" CI_END="1.6557605062706968" CI_START="1.2836540374129815" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4578832802605777" ESTIMABLE="YES" EVENTS_1="864" EVENTS_2="218" I2="18.297666226755183" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.21899751944950874" LOG_CI_START="0.10844799110989765" LOG_EFFECT_SIZE="0.1637227552797032" METHOD="MH" NO="11" P_CHI2="0.26858590259991877" P_Q="0.0" P_Z="6.422231212902559E-9" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2394" TOTAL_2="786" WEIGHT="100.0" Z="5.805374452835269">
<NAME>SGA of relief weeks 1-4 of DB treatment</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9570665172630344" CI_START="1.3174347647862326" EFFECT_SIZE="1.6057108914251772" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="91" LOG_CI_END="0.29160558681760973" LOG_CI_START="0.11972911952421111" LOG_EFFECT_SIZE="0.20566735317091042" ORDER="10839" O_E="0.0" SE="0.10096108769037698" STUDY_ID="STD-Kellow-2003" TOTAL_1="259" TOTAL_2="261" VAR="0.01019314122762399" WEIGHT="30.7790594815801"/>
<DICH_DATA CI_END="1.6381366073620334" CI_START="1.1831044050135793" EFFECT_SIZE="1.392151800697044" ESTIMABLE="YES" EVENTS_1="719" EVENTS_2="127" LOG_CI_END="0.2143501155866213" LOG_CI_START="0.07302307135705853" LOG_EFFECT_SIZE="0.1436865934718399" ORDER="10840" O_E="0.0" SE="0.08301620536059681" STUDY_ID="STD-Tack-2005" TOTAL_1="2135" TOTAL_2="525" VAR="0.006891690352472783" WEIGHT="69.2209405184199"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Tegaserod 4mg vs placebo</NAME>
<DICH_OUTCOME CHI2="1.864669069335015" CI_END="1.3123020098457205" CI_START="1.016378752092911" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1549008092195678" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="281" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.11803379396934074" LOG_CI_START="0.007055577329476518" LOG_EFFECT_SIZE="0.06254468564940864" METHOD="MH" NO="1" P_CHI2="0.39363374416676966" P_Q="0.0" P_Z="0.027162244990738296" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="846" TOTAL_2="839" WEIGHT="100.0" Z="2.2091782515306075">
<NAME>SGA of Relief at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 4mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.280670858848585" CI_START="0.83785689671096" EFFECT_SIZE="1.0358662613981764" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="105" LOG_CI_END="0.10743752743940205" LOG_CI_START="-0.07683015115002552" LOG_EFFECT_SIZE="0.01530368814468825" ORDER="10841" O_E="0.0" SE="0.10823974654314958" STUDY_ID="STD-B307" TOTAL_1="282" TOTAL_2="284" VAR="0.01171584273172526" WEIGHT="37.11238165152594"/>
<DICH_DATA CI_END="1.463325973828531" CI_START="0.9291463595542754" EFFECT_SIZE="1.1660377358490566" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="89" LOG_CI_END="0.16534108133086722" LOG_CI_START="-0.03191587035481363" LOG_EFFECT_SIZE="0.06671260548802678" ORDER="10842" O_E="0.0" SE="0.11586970985782756" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="265" TOTAL_2="267" VAR="0.013425789662537142" WEIGHT="31.450032441044442"/>
<DICH_DATA CI_END="1.6099740894809098" CI_START="1.0244745766518144" EFFECT_SIZE="1.2842809364548495" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="87" LOG_CI_END="0.20681888666165502" LOG_CI_START="0.010501185424547373" LOG_EFFECT_SIZE="0.10866003604310118" ORDER="10843" O_E="0.0" SE="0.11531798949497098" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="299" TOTAL_2="288" VAR="0.013298238701162238" WEIGHT="31.437585907429614"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.4207584790284" CI_END="1.4896177909815376" CI_START="0.818159607131499" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.103967892035609" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" I2="68.85103206213974" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.17307485058609196" LOG_CI_START="-0.08716196560142987" LOG_EFFECT_SIZE="0.042956442492331035" METHOD="MH" NO="2" P_CHI2="0.04034136764077989" P_Q="0.0" P_Z="0.517599765705381" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.048140747213254856" TOTALS="YES" TOTAL_1="846" TOTAL_2="839" WEIGHT="100.0" Z="0.647049725110892">
<NAME>Abdominal pain and discomfort at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 4mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0866281410584933" CI_START="0.6392695274114848" EFFECT_SIZE="0.8334556126192223" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="87" LOG_CI_END="0.03608094802713637" LOG_CI_START="-0.1943159969464833" LOG_EFFECT_SIZE="-0.07911752445967349" ORDER="10844" O_E="0.0" SE="0.1353363059607753" STUDY_ID="STD-B307" TOTAL_1="282" TOTAL_2="284" VAR="0.018315915711108587" WEIGHT="35.16204686078807"/>
<DICH_DATA CI_END="1.7404590283633725" CI_START="0.8968304409999388" EFFECT_SIZE="1.2493584905660378" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="50" LOG_CI_END="0.2406638041413419" LOG_CI_START="-0.04728965896133701" LOG_EFFECT_SIZE="0.09668707259000245" ORDER="10845" O_E="0.0" SE="0.16914528961914435" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="265" TOTAL_2="267" VAR="0.02861012900034422" WEIGHT="30.445936401492546"/>
<DICH_DATA CI_END="1.7377380788573826" CI_START="1.0009481495006227" EFFECT_SIZE="1.3188577308978646" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="65" LOG_CI_END="0.23998431786692082" LOG_CI_START="4.115810067959798E-4" LOG_EFFECT_SIZE="0.1201979494368584" ORDER="10846" O_E="0.0" SE="0.1407262115358108" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="299" TOTAL_2="288" VAR="0.01980386661322177" WEIGHT="34.39201673771939"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.025407196741674" CI_END="1.4295727675237306" CI_START="1.0249996086189372" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2105005275521836" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="190" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.1552062665353471" LOG_CI_START="0.010723699562828393" LOG_EFFECT_SIZE="0.08296498304908775" METHOD="MH" NO="3" P_CHI2="0.5988743477850678" P_Q="0.0" P_Z="0.024391456301966943" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="846" TOTAL_2="839" WEIGHT="99.99999999999999" Z="2.250906557953348">
<NAME>Bowel habit</NAME>
<GROUP_LABEL_1>Tegaserod 4mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4240609761936545" CI_START="0.8160567568305079" EFFECT_SIZE="1.0780141843971631" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="71" LOG_CI_END="0.15352858554906187" LOG_CI_START="-0.08827963497027659" LOG_EFFECT_SIZE="0.03262447528939265" ORDER="10847" O_E="0.0" SE="0.1420393457030555" STUDY_ID="STD-B307" TOTAL_1="282" TOTAL_2="284" VAR="0.02017517572775211" WEIGHT="37.0872149190566"/>
<DICH_DATA CI_END="1.7837020093059273" CI_START="0.9563503776438884" EFFECT_SIZE="1.3060796645702306" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="54" LOG_CI_END="0.2513223015402252" LOG_CI_START="-0.019382966302113842" LOG_EFFECT_SIZE="0.11596966761905568" ORDER="10848" O_E="0.0" SE="0.15901361434327724" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="265" TOTAL_2="267" VAR="0.0252853295465125" WEIGHT="28.20078493997788"/>
<DICH_DATA CI_END="1.6837295800576468" CI_START="0.9645848718546179" EFFECT_SIZE="1.2744018523282736" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="65" LOG_CI_END="0.22627234172462132" LOG_CI_START="-0.015659553653594695" LOG_EFFECT_SIZE="0.10530639403551331" ORDER="10849" O_E="0.0" SE="0.14211199292736057" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="299" TOTAL_2="288" VAR="0.02019581853378618" WEIGHT="34.712000140965515"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.783458565789237" CI_END="0.6633208728723294" CI_START="0.384244549140504" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5237827110064167" ESTIMABLE="YES" I2="35.761204897054604" I2_Q="24.356637088090793" ID="CMP-002.04" NO="4" P_CHI2="0.16858044222571622" P_Q="0.26660357992874995" P_Z="1.8795825105145916E-13" Q="2.643986098726346" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2562" TOTAL_2="2541" UNITS="" WEIGHT="100.0" Z="7.357093110369482">
<NAME>Weekly frequency of bowel movements</NAME>
<GROUP_LABEL_1>Tegaserod 4mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6044099350021823" CI_END="0.6181538714840198" CI_START="0.25524271223581846" DF="1.0" EFFECT_SIZE="0.43669829185991915" ESTIMABLE="YES" I2="61.60358680250688" ID="CMP-002.04.01" NO="1" P_CHI2="0.10656686125609194" P_Z="2.394322456911114E-6" STUDIES="2" TAU2="0.0" TOTAL_1="854" TOTAL_2="847" WEIGHT="59.13510080959381" Z="4.716928109505878">
<NAME>Complete spontaneous bowel movements (CSBM)</NAME>
<CONT_DATA CI_END="0.8688124693863908" CI_START="0.33118753061360895" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.3" ORDER="10850" SD_1="2.3" SD_2="1.7" SE="0.1371517392700832" STUDY_ID="STD-Johanson-2004" TOTAL_1="437" TOTAL_2="431" WEIGHT="26.945557565451992"/>
<CONT_DATA CI_END="0.5459436367277353" CI_START="0.054056363272264873" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.3" ORDER="10851" SD_1="2.0" SD_2="1.6" SE="0.12548375310347903" STUDY_ID="STD-Kamm-2005" TOTAL_1="417" TOTAL_2="416" WEIGHT="32.18954324414182"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8330793893545225" CI_END="1.0522178970859761" CI_START="0.41248446020053825" DF="1.0" EFFECT_SIZE="0.7323511786432572" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.36138366958911006" P_Z="7.20849207812502E-6" STUDIES="2" TAU2="0.0" TOTAL_1="854" TOTAL_2="847" WEIGHT="19.03039863654768" Z="4.487437583892582">
<NAME>Spontaneous bowel movements (SBM)</NAME>
<CONT_DATA CI_END="1.3815770428825274" CI_START="0.41842295711747335" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="4.6" ORDER="10852" SD_1="4.0" SD_2="3.2" SE="0.2457070878246464" STUDY_ID="STD-Johanson-2004" TOTAL_1="437" TOTAL_2="431" WEIGHT="8.395652298660362"/>
<CONT_DATA CI_END="1.0278873329853764" CI_START="0.17211266701462458" EFFECT_SIZE="0.6000000000000005" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.1" ORDER="10853" SD_1="3.1" SD_2="3.2" SE="0.21831387533673915" STUDY_ID="STD-Kamm-2005" TOTAL_1="417" TOTAL_2="416" WEIGHT="10.634746337887316"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7019831427061858" CI_END="0.8764750258477816" CI_START="0.2792316215727883" DF="1.0" EFFECT_SIZE="0.577853323710285" ESTIMABLE="YES" I2="41.245011486425135" ID="CMP-002.04.03" NO="3" P_CHI2="0.19202891786680765" P_Z="1.4903991076635343E-4" STUDIES="2" TAU2="0.0" TOTAL_1="854" TOTAL_2="847" WEIGHT="21.83450055385851" Z="3.7926637438341477">
<NAME>Bowel movements</NAME>
<CONT_DATA CI_END="1.2478374099838696" CI_START="0.35216259001613015" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.4" ORDER="10854" SD_1="3.7" SD_2="3.0" SE="0.22849267308805365" STUDY_ID="STD-Johanson-2004" TOTAL_1="437" TOTAL_2="431" WEIGHT="9.708346237644509"/>
<CONT_DATA CI_END="0.8007111733347929" CI_START="-7.111733347939797E-4" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.9" ORDER="10855" SD_1="3.0" SD_2="2.9" SE="0.20444823297547915" STUDY_ID="STD-Kamm-2005" TOTAL_1="417" TOTAL_2="416" WEIGHT="12.126154316214004"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8903292408713526" CI_END="2.5949929402428498" CI_START="1.116935758197924" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7024806628060147" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="33" I2="30.8037308788719" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.41413618067474856" LOG_CI_START="0.04802819490389958" LOG_EFFECT_SIZE="0.23108218778932405" METHOD="MH" NO="5" P_CHI2="0.23570765610646183" P_Q="0.0" P_Z="0.013353374175614332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1166" TOTAL_2="1151" WEIGHT="100.0" Z="2.4742031484627587">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Tegaserod 4mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2012051533117853" CI_START="0.6204283672197494" EFFECT_SIZE="1.1686274509803922" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.3426605208810106" LOG_CI_START="-0.20730835359641045" LOG_EFFECT_SIZE="0.06767608364230009" ORDER="10857" O_E="0.0" SE="0.323054439257872" STUDY_ID="STD-Johanson-2004" TOTAL_1="450" TOTAL_2="447" VAR="0.1043641707242181" WEIGHT="51.37787420874998"/>
<DICH_DATA CI_END="3.9679187907496796" CI_START="0.7926961020649124" EFFECT_SIZE="1.7735145217159605" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.5985627751025533" LOG_CI_START="-0.10089327736338312" LOG_EFFECT_SIZE="0.2488347488695851" ORDER="10858" O_E="0.0" SE="0.41086394758179107" STUDY_ID="STD-Kamm-2005" TOTAL_1="417" TOTAL_2="416" VAR="0.16880918342249276" WEIGHT="27.141928493621528"/>
<DICH_DATA CI_END="6.693131065036453" CI_START="1.2475437329412409" EFFECT_SIZE="2.8896321070234112" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.8256293294506518" LOG_CI_START="0.09605577885827546" LOG_EFFECT_SIZE="0.4608425541544636" ORDER="10856" O_E="0.0" SE="0.428555115065282" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="299" TOTAL_2="288" VAR="0.1836594866486171" WEIGHT="21.480197297628486"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Tegaserod 12mg vs 4mg</NAME>
<DICH_OUTCOME CHI2="1.4101931150757754" CI_END="1.2199488149916387" CI_START="0.966460735898337" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0858326894577834" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="327" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.08634160950014474" LOG_CI_START="-0.01481578522474148" LOG_EFFECT_SIZE="0.0357629121377016" METHOD="MH" NO="1" P_CHI2="0.49406092971707394" P_Q="0.0" P_Z="0.16579553689478935" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="836" TOTAL_2="846" WEIGHT="100.0" Z="1.3858407477337162">
<NAME>SGA of Relief at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Tegaserod 4mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod 4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod 12</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3489295736246916" CI_START="0.8993153791174652" EFFECT_SIZE="1.1014141414141414" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="108" LOG_CI_END="0.12998927614737427" LOG_CI_START="-0.04608797968923989" LOG_EFFECT_SIZE="0.04195064822906722" ORDER="10859" O_E="0.0" SE="0.10342865167490049" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="282" VAR="0.010697485987287895" WEIGHT="32.807911275458046"/>
<DICH_DATA CI_END="1.4355124353569564" CI_START="0.9627365901308363" EFFECT_SIZE="1.1755936147776445" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="103" LOG_CI_END="0.15700695899449957" LOG_CI_START="-0.016492521910882227" LOG_EFFECT_SIZE="0.07025721854180865" ORDER="10860" O_E="0.0" SE="0.10191445392010288" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="265" VAR="0.010386555917832774" WEIGHT="31.806375469507675"/>
<DICH_DATA CI_END="1.2136505030071862" CI_START="0.8087140422256734" EFFECT_SIZE="0.9907049026507154" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="116" LOG_CI_END="0.08409364022510389" LOG_CI_START="-0.09220501588755677" LOG_EFFECT_SIZE="-0.0040556878312264155" ORDER="10861" O_E="0.0" SE="0.10355870329299924" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="299" VAR="0.01072440502772745" WEIGHT="35.385713255034275"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18320251745432475" CI_END="1.2274135790168434" CI_START="0.8965980619544186" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.049045583453378" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="223" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.08899092362402795" LOG_CI_START="-0.047402204220406884" LOG_EFFECT_SIZE="0.02079435970181052" METHOD="MH" NO="2" P_CHI2="0.9124689658307801" P_Q="0.0" P_Z="0.5500879844410501" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="836" TOTAL_2="846" WEIGHT="100.0" Z="0.5976282931733152">
<NAME>Abdominal pain and discomfort at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Tegaserod 4mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod 4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod 12</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4268114038956434" CI_START="0.8211612532593614" EFFECT_SIZE="1.0824242424242425" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="72" LOG_CI_END="0.15436657181094626" LOG_CI_START="-0.08557155113370347" LOG_EFFECT_SIZE="0.03439751033862137" ORDER="10862" O_E="0.0" SE="0.140940841130551" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="282" VAR="0.019864320698587214" WEIGHT="32.08586248238716"/>
<DICH_DATA CI_END="1.4487817923037862" CI_START="0.7940218841509246" EFFECT_SIZE="1.0725504409810318" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="62" LOG_CI_END="0.16100297930511662" LOG_CI_START="-0.10016752775550622" LOG_EFFECT_SIZE="0.0304177257748052" ORDER="10863" O_E="0.0" SE="0.15341284866227006" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="265" VAR="0.023535502134672575" WEIGHT="28.086333040567748"/>
<DICH_DATA CI_END="1.2870420411923642" CI_START="0.7856702588926734" EFFECT_SIZE="1.0055797599938852" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="89" LOG_CI_END="0.1095927333532215" LOG_CI_START="-0.10475968651816518" LOG_EFFECT_SIZE="0.00241652341752818" ORDER="10864" O_E="0.0" SE="0.12591167249404353" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="299" VAR="0.01585374927024728" WEIGHT="39.8278044770451"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05726428478862346" CI_END="1.070589903183664" CI_START="0.7764514754109955" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9117352191766372" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="232" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.02962314320181501" LOG_CI_START="-0.10988568046309764" LOG_EFFECT_SIZE="-0.04013126863064133" METHOD="MH" NO="3" P_CHI2="0.9717739005042026" P_Q="0.0" P_Z="0.2594842631145645" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="836" TOTAL_2="846" WEIGHT="100.0" Z="1.1276109869420614">
<NAME>Bowel habit</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Tegaserod 4mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tegaserod 4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod 12</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1840494819140952" CI_START="0.669766873113762" EFFECT_SIZE="0.8905263157894737" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="76" LOG_CI_END="0.07336985211089349" LOG_CI_START="-0.1740763366105419" LOG_EFFECT_SIZE="-0.05035324224982421" ORDER="10865" O_E="0.0" SE="0.1453511161333599" STUDY_ID="STD-B307" TOTAL_1="275" TOTAL_2="282" VAR="0.021126946961213477" WEIGHT="32.545725859044246"/>
<DICH_DATA CI_END="1.25083356687489" CI_START="0.700102275019909" EFFECT_SIZE="0.9357945425361156" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="70" LOG_CI_END="0.09719952728222775" LOG_CI_START="-0.15483851108253877" LOG_EFFECT_SIZE="-0.028819491900155512" ORDER="10866" O_E="0.0" SE="0.1480483913438749" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="267" TOTAL_2="265" VAR="0.021918326179509135" WEIGHT="30.471970561767822"/>
<DICH_DATA CI_END="1.1833159759610243" CI_START="0.7006990613431374" EFFECT_SIZE="0.9105758582502769" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="86" LOG_CI_END="0.07310072796954376" LOG_CI_START="-0.15446846428717073" LOG_EFFECT_SIZE="-0.04068386815881349" ORDER="10867" O_E="0.0" SE="0.13367527001726354" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="294" TOTAL_2="299" VAR="0.017869077814188315" WEIGHT="36.98230357918794"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.77916731244167" CI_END="0.3233056987363993" CI_START="0.023704303111517222" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.17350500092395826" ESTIMABLE="YES" I2="26.244629029532874" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.23758880938453408" P_Q="0.9749295360296617" P_Z="0.023201115921683807" Q="0.050780197478015765" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2613" TOTAL_2="2562" UNITS="" WEIGHT="100.00000000000001" Z="2.2701066010675457">
<NAME>Weekly frequency of bowel movements</NAME>
<GROUP_LABEL_1>Tegaserod 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Tegaserod 4mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T4mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T12mg</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1452917869421793" CI_END="0.35865636363190134" CI_START="-0.04218305608291095" DF="1.0" EFFECT_SIZE="0.1582366537744952" ESTIMABLE="YES" I2="53.386294298671444" ID="CMP-003.04.01" NO="1" P_CHI2="0.14300791096679477" P_Z="0.1217563805983988" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="854" WEIGHT="55.86590193702267" Z="1.547443326072074">
<NAME>CSBM</NAME>
<CONT_DATA CI_END="0.2915540499186182" CI_START="-0.2915540499186182" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.9" ORDER="10868" SD_1="2.1" SD_2="2.3" SE="0.1487547996893613" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="437" WEIGHT="26.39912399499413"/>
<CONT_DATA CI_END="0.5759608737022324" CI_START="0.024039126297767333" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.6" ORDER="10869" SD_1="2.1" SD_2="2.0" SE="0.14079895134756384" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="417" WEIGHT="29.46677794202854"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1232533444784543" CI_END="0.5256570259917421" CI_START="-0.13597475722278224" DF="1.0" EFFECT_SIZE="0.19484113438447997" ESTIMABLE="YES" I2="52.90246439029464" ID="CMP-003.04.02" NO="2" P_CHI2="0.14507814300857313" P_Z="0.24835142094494955" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="854" WEIGHT="20.504772027392033" Z="1.1543629426178579">
<NAME>SBM</NAME>
<CONT_DATA CI_END="0.4164475499980448" CI_START="-0.6164475499980441" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.5" ORDER="10870" SD_1="3.8" SD_2="4.0" SE="0.2634984898047703" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="437" WEIGHT="8.413471537689185"/>
<CONT_DATA CI_END="0.830801621518723" CI_START="-0.030801621518724176" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.7" ORDER="10871" SD_1="3.3" SD_2="3.1" SE="0.21980078456381436" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="417" WEIGHT="12.091300489702848"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.45984198354302" CI_END="0.49925699727854644" CI_START="-0.1170798957501232" DF="1.0" EFFECT_SIZE="0.19108855076421163" ESTIMABLE="YES" I2="59.34698217648698" ID="CMP-003.04.03" NO="3" P_CHI2="0.11679077208834288" P_Z="0.2242398818685748" STUDIES="2" TAU2="0.0" TOTAL_1="871" TOTAL_2="854" WEIGHT="23.629326035585315" Z="1.2153310359708973">
<NAME>Bowel movements</NAME>
<CONT_DATA CI_END="0.37675148046145146" CI_START="-0.5767514804614525" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="6.2" ORDER="10872" SD_1="3.5" SD_2="3.7" SE="0.24324502094018402" STUDY_ID="STD-Johanson-2004" TOTAL_1="440" TOTAL_2="437" WEIGHT="9.872873493118146"/>
<CONT_DATA CI_END="0.8038876832025699" CI_START="-0.0038876832025691033" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="5.3" ORDER="10873" SD_1="3.0" SD_2="3.0" SE="0.20606893105607244" STUDY_ID="STD-Kamm-2005" TOTAL_1="431" TOTAL_2="417" WEIGHT="13.756452542467168"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Tegaserod 4mg &amp; 12mg vs placebo</NAME>
<DICH_OUTCOME CHI2="2.46426547798504" CI_END="1.2678918022026593" CI_START="1.075938830140086" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1679786052861305" ESTIMABLE="YES" EVENTS_1="1012" EVENTS_2="573" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.10308219383652056" LOG_CI_START="0.0317875812859746" LOG_EFFECT_SIZE="0.06743488756124759" METHOD="MH" NO="1" P_CHI2="0.4817839857102214" P_Q="0.0" P_Z="2.0914018136017527E-4" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2449" TOTAL_2="1591" WEIGHT="99.99999999999999" Z="3.7077121592560314">
<NAME>SGA of Relief at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 4mg &amp; 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3055308291894614" CI_START="0.9062678976588379" EFFECT_SIZE="1.0877318970676242" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="105" LOG_CI_END="0.11578713183784343" LOG_CI_START="-0.04274340356277644" LOG_EFFECT_SIZE="0.03652186413753351" ORDER="10874" O_E="0.0" SE="0.09312162123313047" STUDY_ID="STD-B307" TOTAL_1="557" TOTAL_2="284" VAR="0.008671636341086615" WEIGHT="20.77110768179306"/>
<DICH_DATA CI_END="1.5443569085404287" CI_START="1.0424052880695893" EFFECT_SIZE="1.268796992481203" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="89" LOG_CI_END="0.18874767520777697" LOG_CI_START="0.018036605864176526" LOG_EFFECT_SIZE="0.10339214053597674" ORDER="10875" O_E="0.0" SE="0.1002765271658527" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="532" TOTAL_2="267" VAR="0.010055381900443994" WEIGHT="17.69970460599151"/>
<DICH_DATA CI_END="1.5657170867946164" CI_START="1.043745839014071" EFFECT_SIZE="1.2783625050880967" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="87" LOG_CI_END="0.19471329109107344" LOG_CI_START="0.01859475714140193" LOG_EFFECT_SIZE="0.10665402411623769" ORDER="10876" O_E="0.0" SE="0.1034528986428403" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="593" TOTAL_2="288" VAR="0.010702502237605788" WEIGHT="17.49078076913064"/>
<DICH_DATA CI_END="1.2651869837252692" CI_START="0.9940711475293881" EFFECT_SIZE="1.121465949884803" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="292" LOG_CI_END="0.10215471523438314" LOG_CI_START="-0.0025825312227681107" LOG_EFFECT_SIZE="0.04978609200580749" ORDER="10877" O_E="0.0" SE="0.06152317702666218" STUDY_ID="STD-Novick-2002" TOTAL_1="767" TOTAL_2="752" VAR="0.0037851013114540127" WEIGHT="44.03840694308479"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.747143957021995" CI_END="1.5075510802811336" CI_START="0.8492401753562742" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1314914687157347" ESTIMABLE="YES" EVENTS_1="454" EVENTS_2="202" I2="74.18403464431297" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.17827203624064555" LOG_CI_START="-0.0709694686713432" LOG_EFFECT_SIZE="0.05365128378465118" METHOD="MH" NO="2" P_CHI2="0.02078402824384218" P_Q="0.0" P_Z="0.3987830091173077" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.047547365023420225" TOTALS="YES" TOTAL_1="1682" TOTAL_2="839" WEIGHT="99.99999999999999" Z="0.8437967342508702">
<NAME>Abdominal pain and discomfort at endpoint</NAME>
<GROUP_LABEL_1>Tegaserod 4mg &amp; 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0839591126026322" CI_START="0.6940620754250829" EFFECT_SIZE="0.8673724179203037" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="87" LOG_CI_END="0.03501290073930907" LOG_CI_START="-0.1586016854400138" LOG_EFFECT_SIZE="-0.061794392350352376" ORDER="10878" O_E="0.0" SE="0.11373016632939281" STUDY_ID="STD-B307" TOTAL_1="557" TOTAL_2="284" VAR="0.012934550733311354" WEIGHT="35.43972920570607"/>
<DICH_DATA CI_END="1.7331517441930238" CI_START="0.9673910865256489" EFFECT_SIZE="1.2948496240601504" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="50" LOG_CI_END="0.23883658855386677" LOG_CI_START="-0.014397918488352408" LOG_EFFECT_SIZE="0.11221933503275719" ORDER="10879" O_E="0.0" SE="0.14875120296762612" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="532" TOTAL_2="267" VAR="0.0221269203843159" WEIGHT="30.764043057166397"/>
<DICH_DATA CI_END="1.6929663335613891" CI_START="1.0331112396476658" EFFECT_SIZE="1.3225061616292646" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="65" LOG_CI_END="0.22864832178649483" LOG_CI_START="0.014147086441343814" LOG_EFFECT_SIZE="0.12139770411391931" ORDER="10880" O_E="0.0" SE="0.12599908743998112" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="593" TOTAL_2="288" VAR="0.01587577003570801" WEIGHT="33.79622773712752"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.556148383826598" CI_END="1.3429046549926666" CI_START="0.9976112560480299" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1574527202525295" ESTIMABLE="YES" EVENTS_1="441" EVENTS_2="190" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.1280451792506323" LOG_CI_START="-0.0010386593571308873" LOG_EFFECT_SIZE="0.0635032599467507" METHOD="MH" NO="3" P_CHI2="0.459289807265052" P_Q="0.0" P_Z="0.05380257035587193" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="839" WEIGHT="100.00000000000001" Z="1.9284227016941373">
<NAME>Bowel habit</NAME>
<GROUP_LABEL_1>Tegaserod 4mg &amp; 12mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tegaserod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3047352328238573" CI_START="0.7970102210440435" EFFECT_SIZE="1.0197486535008977" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="71" LOG_CI_END="0.11552239014952886" LOG_CI_START="-0.09853610907494882" LOG_EFFECT_SIZE="0.008493140537289993" ORDER="10881" O_E="0.0" SE="0.12573902205111848" STUDY_ID="STD-B307" TOTAL_1="557" TOTAL_2="284" VAR="0.01581030166637166" WEIGHT="37.10544297282198"/>
<DICH_DATA CI_END="1.6705606184760717" CI_START="0.9563730204114635" EFFECT_SIZE="1.2639933166248956" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="54" LOG_CI_END="0.22286223920313064" LOG_CI_START="-0.019372683969578613" LOG_EFFECT_SIZE="0.10174477761677603" ORDER="10882" O_E="0.0" SE="0.14228999295385772" STUDY_ID="STD-Lefkowitz-1999b" TOTAL_1="532" TOTAL_2="267" VAR="0.020246442094808883" WEIGHT="28.37126402608529"/>
<DICH_DATA CI_END="1.5649101607799651" CI_START="0.9478392174157492" EFFECT_SIZE="1.2179011544947465" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="65" LOG_CI_END="0.1944894103825033" LOG_CI_START="-0.023265326070362302" LOG_EFFECT_SIZE="0.08561204215607049" ORDER="10883" O_E="0.0" SE="0.1279102100957429" STUDY_ID="STD-Muller_x002d_Lissner-2001" TOTAL_1="593" TOTAL_2="288" VAR="0.016361021846737094" WEIGHT="34.52329300109274"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>